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Bradford-Hill considerationsSystematic consideration of scientiﬁc support is a critical element in developing and, ultimately, using
adverse outcome pathways (AOPs) for various regulatory applications. Though weight of evidence
(WoE) analysis has been proposed as a basis for assessment of the maturity and level of conﬁdence in
an AOP, methodologies and tools are still being formalized. The Organization for Economic
Co-operation and Development (OECD) Users’ Handbook Supplement to the Guidance Document for
Developing and Assessing AOPs (OECD 2014a; hereafter referred to as the OECD AOP Handbook) provides
tailored Bradford-Hill (BH) considerations for systematic assessment of conﬁdence in a given AOP. These
considerations include (1) biological plausibility and (2) empirical support (dose-response, temporality,
and incidence) for Key Event Relationships (KERs), and (3) essentiality of key events (KEs). Here, we test
the application of these tailored BH considerations and the guidance outlined in the OECD AOP Handbook
using a number of case examples to increase experience in more transparently documenting rationales
for assigned levels of conﬁdence to KEs and KERs, and to promote consistency in evaluation within
and across AOPs. The major lessons learned from experience are documented, and taken together with
the case examples, should contribute to better common understanding of the nature and form of docu-
mentation required to increase conﬁdence in the application of AOPs for speciﬁc uses. Based on the tai-
lored BH considerations and deﬁning questions, a prototype quantitative model for assessing the WoE of
an AOP using tools of multi-criteria decision analysis (MCDA) is described. The applicability of the
approach is also demonstrated using the case example aromatase inhibition leading to reproductive dys-
function in ﬁsh. Following the acquisition of additional experience in the development and assessment of
AOPs, further reﬁnement of parameterization of the model through expert elicitation is recommended.
Overall, the application of quantitative WoE approaches hold promise to enhance the rigor, transparency
and reproducibility for AOP WoE determinations and may play an important role in delineating areas
where research would have the greatest impact on improving the overall conﬁdence in the AOP.
 2015 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).h Canada
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A large number of substances in commerce require risk evalua-
tion to protect human health and the environment. A key challenge
for the regulatory community is assessing the potential for risks of
substances with limited toxicity or toxicology data. Accordingly,
various regulatory mandates and related initiatives in Canada,
USA, the European Union and, more recently, the Asian Paciﬁc
region (see, for example, Council of Labor Affairs, Taiwan, 2012;
Dellarco et al., 2010; European Commission, 2006; Hughes et al.,
2009; Lowell Center for Sustainable Production, 2012; Meek and
Armstrong, 2007, Mitchell et al., 2013) reﬂect the rapidly growing
need for more efﬁcient methods and novel strategies to assess the
hazards and risks of a wide array of chemicals. Due to costs and
time involved, as well as the desire to reduce animal use in
response to ethical considerations, traditional resource-intensive
standard in vivo toxicology studies are not feasible for the regula-
tory testing of all chemicals requiring evaluation. Adverse outcome
pathways (AOPs) hold great promise as important tools to enhance
efﬁciencies and the future success of risk assessment in the imple-
mentation of pathway- and mechanistic-based approaches that are
able to accommodate substances and groups of substances with
varying amounts and types of toxicological information (e.g.,
OECD, 2014b; CCA, 2012; Ankley et al., 2010; NRC, 2010; NRC,
2007). However, it is important to note that these promising con-
cepts and approaches supporting the application of
pathway-based data and predictive modeling in hazard character-
ization and risk assessment need further development, evaluation
and acceptance before being used routinely.
The generation and consideration of mechanistic data has the
potential to increase our understanding of the modes of action
(MoA) underlying the toxicity of various individual chemicals
and groups of chemicals. It is anticipated that MoA information
will lead to improved estimation of potential risk to human health
and the environment. Investigators continue to elucidate the
modes and mechanisms underlying toxicity-related adverse effects
by applying emerging and increasingly more sophisticated compu-
tational, molecular and in vitro technologies. Such approaches have
the potential to be used qualitatively and/or quantitatively in a
predictive manner to identify potential toxicities in the absence
of deﬁnitive data on adverse effects. A major challenge faced by
both research and regulatory scientists is the integration of data
and information being generated from diverse sources at many dif-
ferent levels of biological organization in a manner that is trans-
parent, informative and suitable for regulatory decision-making.
Conceptually, an AOP is similar to a MoA (OECD, 2013) with the
MoA representing a chemical and species speciﬁc application of the
more general AOP. The AOP construct (Fig. 1) portrays a MoA in astructured framework that organizes and links knowledge of Key
Events (KEs; a change in biological state that is both measurable
and essential to the progression of a deﬁned biological perturba-
tion) in a sequence that commences with the molecular initiating
event (MIE; the initial point of chemical-biological interaction
within the organism that starts the pathway) and proceeds
through a series of higher order biological events, culminating with
the in vivo adverse outcome (AO) of interest to risk assessment. The
series of biological events, or KEs, are connected to one another via
linkages deﬁned as Key Event Relationships (KERs). An AOP that is
anchored to both a MIE and an AO provides a consistent structure
that facilitates effective application and integration of diverse
information on MoAs for various hazard and risk assessment uses,
and provides a tool for the identiﬁcation of key uncertainties and
research needs (Ankley et al., 2010; OECD, 2013). Villeneuve
et al. (2014a,b) provide detailed discussion of deﬁnitions of MIEs,
KEs and KERs as well as strategies, principles and best practices
to use when developing AOPs, and refer to work reported here with
respect to conduct of WoE evaluations; other products from the
2014 workshop ‘‘Advancing AOPs for Integrated Toxicology and
Regulatory Applications’’ can be found at https://aopkb.org/
saop/workshops/somma.html#manuscripts.
Under the auspices of the Organisation for Economic
Cooperation and Development (OECD), scientists across the world
and from all sectors have an opportunity to develop AOPs which
will be peer- reviewed and publically accessible through a
wiki-based tool (AOP-Wiki; aopwiki.org). Using the wiki format,
contributions to improving the scientiﬁc basis and range of appli-
cations of AOPs can be made by experts from all sectors and
regions. When fully actualized, the AOP-Wiki will serve as a repos-
itory of information of AOPs, KEs and KERs for a wide spectrum of
toxicologically-relevant pathways. This organized and integrated
information is envisioned to address or inform a number of analyt-
ical domains in the decision-making process including: (1) efﬁcient
grouping of chemicals based on common pathways of toxicity and
potential consideration of non-test methods, such as read-across
and (quantitative) structure-activity relationship ((Q)SAR) model-
ing or targeted testing to ﬁll data needs; (2) identiﬁcation of
research priorities relevant to data gaps in regulatory test batter-
ies; (3) providing a framework for priority setting; and, (4) hazard
characterization and risk assessment that incorporate qualitative
and quantitative determinations of human and/or ecological rele-
vance and variability, dose–response extrapolation and potential
for combined effects of chemicals (OECD, 2013, 2014a,b; Meek
et al., 2014a,b).
In order for AOPs to be considered for a speciﬁed application by
the regulatory community, it is critical to standardize AOP devel-
opment and provide a clear and transparent evaluation of
Fig. 1. Framework of an AOP.
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dence (WoE) evaluation (Weed, 2005; Linkov et al., 2009, 2015;
Rhomberg et al., 2013) was incorporated as a key element of the
OECD guidance on developing and assessing AOPs (OECD, 2013).
While approaches for conducting WoE evaluations may differ,
the essence of all approaches requires considering the collective
body of evidence to address the speciﬁc questions at hand. The
purpose of a WoE evaluation is to document certainty in inferring
responses beyond interpolation within the range of empirical
observations in a transparent manner. Conﬁdence in inference is
underpinned by the degree of certainty that the lines of evidence
support the hypothesized inference. The Bradford-Hill (BH) consid-
erations (Hill, 1965), originally developed for the evaluation of
causality of associations observed in epidemiological studies, and
more recently evolved to increase consistency for WoE determina-
tions in the application of MoA/species concordance analysis
(Meek et al., 2014a,b) , provide a useful approach for evaluating
the extent of support for hypothesized AOPs. Thus, the BH consid-
erations have been adopted for assessing the WoE of KEs, KERs and
overall AOPs (OECD, 2014a). However, there is a need for tailoring
of these considerations to address the AOP context (i.e., the
non-chemical related elements of the pathway between exposure
and effect). Moreover, there is a need for explicit examination
and illustration using case examples of how these tailored BH con-
siderations can be applied for the practical purpose of AOP assess-
ment, both qualitatively and, potentially, quantitatively (Linkov
et al., 2009, 2015).
Improvement of WoE analysis in the development of AOPs was
addressed in a workshop held March 2–7, 2014 in Somma
Lombardo, Italy entitled ‘‘Advancing AOPs for Integrated
Toxicology and Regulatory Applications.’’ The speciﬁc objectives
of one of the workshop groups were to: (1) Provide guidance and
documentation for applying the evolved BH considerations for
the WoE evaluation of KEs, KERs and overall AOPs; (2) Illustrate
the application of the WoE approach using the evolved BH consid-
erations through the use of case examples; (3) Illustrate how con-
ﬁdence levels in an AOP can help to inform different regulatoryapplications; (4) Explore challenges and opportunities for con-
structing a quantitative WoE methodology for AOPs; and, (5)
Contribute to the development of a transparent, user friendly
approach that has been incorporated in the AOP-Wiki to promote
greater consistency in AOP development and facilitate communica-
tion of the scientiﬁc conﬁdence in an AOP for regulatory
applications.
Importantly, preparation of this manuscript has been coordi-
nated with the development of the OECD AOP Handbook (OECD,
2014a) for which there is overlap of contributors. Speciﬁcally, the
guidance in the OECD AOP Handbook (OECD, 2014a) has been
informed and ‘‘tested’’ by example. The case examples and early
testing illustrated in this paper are essential in continuing evolu-
tion of the guidance, including clariﬁcation of the elements of
WoE and associated terminology and illustration and revision of
categories of the extent of WoE based on practical application.
Furthermore, this testing supports advancement in the develop-
ment of AOPs and provides practical recommendations to facilitate
consistency in the evaluation and documentation of WoE of AOPs.
Accordingly, lessons learned in the application of the guidance are
highlighted. Finally, a prototype multi-criteria decision analysis
(MCDA) model is introduced to illustrate an approach that may
prove fruitful in the future for quantitatively weighting relevant
BH considerations in AOP WoE analyses.
2. Application of evolved BH considerations for WoE in
developing an AOP
The challenges in conducting WoE evaluations for diverse AOPs
and opportunities for improving the systematic WoE analysis to
enhance communication of the scientiﬁc conﬁdence in KEs, KERs
and AOPs were discussed. The basis for these discussions included
the initial evolution of WoE considerations included in a recent
update of the human-oriented more chemical speciﬁc
MoA/species concordance framework (Meek et al., 2014a,b), and
the initial tables and narrative on WoE in the OECD guidance
(OECD, 2013). Subsequently, in an iterative manner, the
Table 1
Guidance for assessing relative level of conﬁdence in the overall AOP based on evolved Bradford-Hill weight of evidence considerations.1 234
Biological Plausibility Deﬁning Question: Is there a mechanistic (i.e., structural or functional) relationship between Key Eventupstream and Key Evendownstream consistent with
established biological knowledge?
High (Strong) Conﬁdence: Extensive understanding of
the Key Event Relationship based on extensive
previous documentation and broad acceptance
(e.g., mutation leading to tumors), i.e., an
established mechanistic basis.
Moderate Conﬁdence: The Key Event Relationship is
plausible based on analogy to accepted biological
relationships but scientiﬁc understanding is not
completely established.
Low (Weak) Conﬁdence: There is empirical support
for a association between Key Events (see Empirical
Evidence below), but the structural or functional
relationship between them is not understood.
Essentiality5 Deﬁning Question: Are downstream Key Events and/or the Adverse Outcome prevented if an upstream Key Event is blocked?
High (Strong) Conﬁdence: Direct evidence from
speciﬁcally designed experimental studies
illustrating essentiality for at least one of the
important Key Events (e.g., stop/reversibility/
recovery studies, antagonism, knockout models,
etc.)
Moderate Conﬁdence: Indirect evidence that
sufﬁcient modiﬁcation of an expected modulating
factor attenuates or augments a Key Event (e.g.,
augmentation of proliferative response in the Key
Eventupstream leading to an increase in Key
Eventdownstream or in the Adverse Outcome).
Low (Weak) Conﬁdence: No or contradictory
experimental evidence of the essentiality of any of the
Key Events.
Empirical Evidence6 7 Deﬁning Questions: Does the empirical evidence support that a change in Key Eventupstream leads to an appropriate change in KeyEventdownstream? Does
KeyEventupstream occur at lower doses and earlier time points than KeyEventdownstream and is the incidence of KeyEventupstream greater than that for the KeyEventdownstream?
Are there inconsistencies in empirical support across taxa, species and stressors that don’t align with an expected pattern for the hypothesized AOP? (Note: In many cases,
evidence that contributes to quantitative understanding of a Key Event Relationship description will also provide empirical support for the relationship, and such relevant
information should be considered as part of the overall weight of evidence evaluation of the concordance of empirical observations and consistency of the Key Event
Relationship.)
High (Strong) Conﬁdence: Multiple studies showing
dependent change in both events following
exposure to a wide range of speciﬁc stressors.
Extensive evidence for temporal, dose-response
and incidence concordance and no or few critical
data gaps or conﬂicting data.
Moderate Conﬁdence: Demonstrated dependent
change in both events following exposure to a small
number of speciﬁc stressors and some evidence
inconsistent with an expected pattern that may be
explained by factors such as experimental design,
technical considerations, differences among
laboratories, etc.
Low (Weak) Conﬁdence: Limited or no studies
reporting dependent change in both events following
exposure to a speciﬁc stressor (i.e., endpoints never
measured in the same study or not at all); and/or
signiﬁcant inconsistencies in empirical support across
taxa and species that don’t align with expected
pattern for hypothesized AOP.
1 Adapted from OECD AOP Handbook (OECD, 2014a,b,c), Annex 1. The BH considerations are rank ordered, as per Meek et al. (2014b) with respect for use in the overall
weight of evidence determination of an AOP (i.e., biological plausibility > essentiality > empirical evidence). The following footnotes are verbatim from OECD AOP Handbook
(OECD, 2014a,b,c), Annex 1, except as indicated with bracketed text.
2 The guidance for ‘‘high’’, ‘‘moderate’’ and ‘‘low’’ draws on limited current experience. Additional delineation of the nature of relevant evidence in these broadly deﬁned
categories requires more experience with larger numbers of documented AOPs.
3 ‘‘Direct evidence’’ implies speciﬁcally designed experiments to consider the relevant element. ‘‘Indirect evidence’’ normally relates to empirical support and is largely
duplicative of Element 3 [empirical evidence].
4 To the extent possible, each of the relevant Bradford Hill considerations is addressed for each of the KERs (biological plausibility and empirical support) and KEs
(essentiality) and separate rationales provided.
5 While the essentiality of each of the KEs is addressed separately, delineation of the degree of conﬁdence is based on consideration of evidence for all of the KEs within the
AOP and therefore, only one rationale is required.
6 This is normally considered on the basis of tabular presentation of available data on temporal and dose-response aspects, in a template that documents the extent of
support. See, for example, Meek and Klaunig (2010).
7 Note that this relates to concordance of dose response, temporal and incidence relationships for KERs rather than the KEs; the deﬁning question is not whether or not
there is a dose response relationship for the KE but rather there is concordance with that for earlier and later KEs. This is normally demonstrated in studies with different
types of stressors.
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the workshop outputs in revising the evaluation and documenta-
tion of levels of conﬁdence by categorical ratings of high (H) or
strong, moderate (M), and low (L) or weak, for KEs, KERs and the
overall AOP. The evaluation of KERs necessitates an understanding
of the scientiﬁc support for (1) the Key Eventupstream, (2) the Key
Eventdownstream and (3) the relationship between these events. The
summary table template found in Annex 1 of the OECD AOP
Handbook (OECD, 2014a), which includes rank-ordered evolved
BH considerations with deﬁning questions and brief narrative
guidance for assessing the relative level of conﬁdence for biological
plausibility, essentiality and empirical evidence was applied in the
case examples presented here. Table 1 (adapted from OECD, 2014a)
outlines, in a streamlined manner, the deﬁning questions that were
considered in developing the case examples for purposes of com-
municating the elements of WoE. AOP developers are directed to
the OECD AOP Handbook (OECD, 2014a), which includes guidance,
current templates and suggested evidence table formats for sum-
marizing data in support of WoE evaluations.
The rank ordering is based on experience in MoA/species con-
cordance analysis and includes biological plausibility and empiri-
cal support (dose-response, temporality, and incidence) for KERs
and essentiality of KEs in the context of the AOP. In rank order,the evolved BH considerations are: (1) biological plausibility; (2)
essentiality; and (3) empirical support (dose-response, temporal-
ity, consistency). While biological plausibility and empirical sup-
port is considered for each of the KERs, essentiality of the KEs is
considered in the context of the overall AOP. The summary table
template and associated text in the OECD AOP Handbook (OECD,
2014a) for each speciﬁc BH consideration are intended to promote
consistency of evaluation within and across AOPs and to explicitly
capture the rationale of AOP developers for the levels of conﬁdence
assigned to KEs and KERs. Although not depicted in Table 1, the
summary table template in the OECD AOP Handbook (OECD,
2014a) includes entry space for summarizing the level of evidence,
as appropriate for a speciﬁc AOP, for each KE and KER for each of
the three BH considerations. The objective of the template is to
clearly delineate the degree of conﬁdence that can be determined
based on thorough review of the available data in the context of
the outlined considerations for low (weak), moderate and high
(strong).
More transparent documentation of articulated considerations
for WoE evaluation of AOPs should increase the collective under-
standing of the importance and value of such analyses to underpin
the scientiﬁc conﬁdence in speciﬁc regulatory applications.
Through transparent consideration of speciﬁed elements based
518 R.A. Becker et al. / Regulatory Toxicology and Pharmacology 72 (2015) 514–537on WoE guidance, it is anticipated that there will be signiﬁcant
beneﬁt imparted from the clarity of the rationales provided for
the KEs and KERs, including to contributors for reﬁning AOPs from
the broader community, peer reviewers, and AOP users, as well as
those interested in learning from the experiences of others to
develop new AOPs.
Based on previous experience in the development of WoE con-
siderations, testing of proposed approaches is the most important
element in their informed evolution. Thus, the objectives of the
application of the case examples presented herein are to contribute
to the further development of the OECD AOP Handbook (OECD,
2014a), to improve upon the current guidance by reducing ambi-
guities, eliminating unnecessary duplicative evaluations of sup-
porting data and increasing transparency. The summaries
presented here represent comparatively early experience in the
development and documentation of applying the BH considera-
tions to AOPs and these procedures are expected to continue to
evolve, perhaps rapidly, as AOPs are developed in the near future.3. Case examples
To illustrate application of WoE evaluation, analyses are pro-
vided for several AOPs:
 Aromatase inhibition leading to reproductive dysfunction in
ﬁsh
 Arylhydrocarbon receptor (AhR) activation leading to induction
of cytochrome P450 ( CYP) monooxygenases and oxidative
stress (see Annex)
 Juvenile hormone agonist-induction leading to increase in male
offspring in the arthropod Cladocera (see Annex)
 Binding of certain organophosphates to neuropathy target
esterase (NTE) leading to delayed neuropathy (see Annex)
 Agonist binding to estrogen receptor a (ERa) leading to an
increased risk of endometrial cancer (see Annex)
 A chemical speciﬁc case example: induction of cytotoxicity and
regenerative hyperplasia by oral hexavalent chromium (Cr(VI))
leading to duodenal tumors in mice – a chemical speciﬁc MoA
analysis (see Annex)
The case example Aromatase Inhibition Leading to
Reproductive Dysfunction in Fish, a relatively well-characterized
AOP (https://aopkb.org/aopwiki/index.php/Aop:25), is presented
in detail below. The other analyses are presented in the accompa-
nying Annex. Evaluation of each KE and KER would be the norm for
consideration of the WoE in the development of a complete AOP.
Essentiality of KEs is also addressed in the context of all of the
KEs in the AOP. However, to gain broader experience across a vari-
ety of AOPs, rather than focus on one AOP in detail, we elected to
examine a subset of KEs and KERs in the six case examples.3.1. Aromatase inhibition leading to reproductive dysfunction (in ﬁsh)
This AOP characterizes the consequences of inhibition of the
enzyme cytochrome P450 aromatase (CYP19) – the MIE – relative
to reproductive effects and, potentially, population-level responses
in ﬁsh (Ankley et al., 2009a,b, 2010). The species used for much of
the work deriving this AOP is the fathead minnow (Pimephales
promelas), a model ﬁsh species in ecotoxicology research and reg-
ulatory applications (Ankley and Villeneuve, 2006). However,
knowledge of basic comparative reproductive endocrinology,
including cross-species conservation of CYP19 structure and func-
tion, suggests a relatively broad biological domain of applicability
of this basic AOP not only to ﬁshes but, potentially, other oviparous
vertebrates as well (Celander et al., 2011;Norris and Carr, 2013).Brieﬂy, aromatase catalyzes the conversion of testosterone (T) to
17b-estradiol (E2), which is involved in different aspects of repro-
duction in ﬁsh, including stimulation of production of vitellogenin
(VTG; an egg yolk precursor protein) in the liver of females,
through activation of the estrogen receptor (ER). Hepatic VTG
enters the bloodstream, is taken up into the ovary, and incorpo-
rated into developing oocytes. A number of environmental con-
taminants, including some pesticides and drugs, can inhibit the
activity of CYP19. Exposure of reproductively-active female ﬁsh
to aromatase inhibitors decreases measured activity of ovarian
CYP19, resulting in a cascade of downstream KEs, including a
depression in plasma E2 concentrations, subsequent decreases in
plasma VTG, lowered deposition of VTG into developing oocytes,
and depressed egg production (fecundity) that can be translated,
via modeling, into population declines (Fig. 2).
There are seven pairs of KEs (and associated KERs) that com-
prise the aromatase inhibition-reproductive dysfunction AOP
(Fig. 2; Table 2). The ﬁrst pair of KEs is inhibition of CYP19 activity
(the MIE) resulting in decreased ovarian production of E2
(described by KER1); then, reduced plasma concentration of E2
(described by KER2); depressed VTG production in the liver
(described by KER3); decreased plasma VTG concentrations
(described by KER4); impaired oocyte development (described by
KER5); reduced fecundity (described by KER6); and, ﬁnally,
decreases in the population (described by KER7). Also indicated
in Table 2 are WoE rankings for the KERs associated with the pairs
of KEs in the AOP. Below, for illustrative purposes, we explore two
quite different types of KERs from the AOP in terms of application
of the WoE considerations summarized in Table 1 (which corre-
sponds to Annex 1 of the OECD AOP Handbook (OECD, 2014a)).
Speciﬁcally, we evaluate biological plausibility, and empirical evi-
dence in assessing the relationship between decreases in the KEs
of plasma E2 and VTG production (KER3), and between the KEs
of fecundity and population status (KER7). As to essentiality of
KEs, we discuss this below in terms of assessment of the overall
AOP.
3.1.1. WoE Evaluation of KER3 (reduction in plasma 17b-estradiol
concentrations leading to reduction in transcription and translation of
vitellogenin)
3.1.1.1. Biological plausibility. Based on well-established knowledge
of normal reproductive biology in oviparous animals, the biological
plausibility of a relationship between plasma E2 concentrations
and hepatic VTG production is high (strong). Vitellogenin synthesis
in ﬁsh is localized in the liver and is well documented to be regu-
lated by estrogens via interaction with ERs (Norris and Carr, 2013).
There is extensive in vitro and in vivo evidence with multiple ﬁsh
species of this relationship. This includes in vivo studies with
females in which the status of the two parameters has been
assessed relative to one another over the course of normal repro-
ductive cycles (Norris and Carr, 2013), and mechanistic in vitro
experiments showing that VTG production in hepatic tissues can
be blocked by ER antagonists (e.g., Sun et al., 2010; Petersen and
Tollefsen, 2012). Indirect evidence for biological plausibility of
the relationship between E2 and VTG production comes from stud-
ies with male ﬁsh, which maintain the ability to produce VTG, but
normally do not express the protein. Exposure of males to estro-
gens (including E2) results in induction of hepatic VTG production,
a response not caused by exposure to other chemical classes or
environmental stressors (Sumpter and Jobling, 1995).
3.1.1.2. Empirical support. Concordance of empirical observations of
dose-response and temporal relationships between E2 and VTG
depressions in ﬁsh also provides strong evidence for linkage of
the two endpoints. For example, intensive time-course/dose-
response studies with fathead minnows conducted with two
Fig. 2. Overview of an adverse outcome pathway relating inhibition of aromatase inhibition to reproductive dysfunction in ﬁsh. E2, 17b-estradiol; VTG, vitellogenin.
Table 2
KEs and WoE analysis of KERs for the adverse outcome pathway of aromatase inhibition leading to reproductive dysfunction in ﬁsh.
Key Event (upstream) Key Event (downstream) Weight-of-evidence for the KER
Aromatase inhibition Ovarian (granulosa cell) E2 synthesis (reduction) KER1: High (Strong)
Ovarian (granulosa cell) E2 synthesis (reduction) Plasma 17b-estradiol concentrations (reduction) KER2: High (Strong)
Plasma 17b-estradiol concentrations (reduction) Transcription and translation of vitellogenin (reduction) KER3: High (Strong)
Transcription and translation of vitellogenin (reduction) Plasma vitellogenin concentrations (reduction) KER4: High (Strong)
Plasma vitellogenin concentrations (reduction) Vitellogenin uptake, impaired oocyte development (reduction) KER5: Moderate
Vitellogenin uptake, impaired oocyte development (reduction) Spawning and cumulative fecundity (reduction) KER6: Moderate
Spawning and cumulative fecundity (reduction) Population trajectory (decrease) KER7: Moderate
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zole fungicide), showed that depressions in plasma E2 precede
those of VTG, and both were dependent on chemical dose with
the decrease in plasma E2 occurring at doses equal to or lower than
those at which VTG decreased (Villeneuve et al., 2009; Ankley
et al., 2009b). In terms of consistency of the relationship across
multiple test systems, several other studies in ﬁsh have shown that
chemicals which decrease plasma E2 also depress vitellogenesis.
For example, Yu et al. (2014) recently reported that polybromi-
nated diphenyl ethers depressed E2 production and hepatic VTG
mRNA expression in zebraﬁsh (Danio rerio). Although not included
in this brief discussion, the OECD AOP Handbook (OECD, 2014a)suggests summarizing empirical evidence in tabular format to
illustrate dose response, temporality and incidence concordance.3.1.2. WoE of KER7 for the AOP of aromatase inhibition leading to
reproductive dysfunction in ﬁsh
3.1.2.1. Biological plausibility. In terms of biological plausibility, it is
intuitive that, in the absence of emigration, decreases in embryo
production would depress population size. Consistent with this,
Miller and Ankley (2004) describe a density-dependent, Leslie
matrix model that utilizes empirical life-history data for the fat-
head minnow, where population trajectories are tightly coupled
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high.
3.1.2.2. Empirical support. There is limited empirical evidence from
the open literature that fathead minnow population size will
decrease if fecundity is decreased by an endocrine-active chemical.
Kidd et al. (2007) conducted a study in which an entire lake was
treated with the ER agonist 17a-ethinylestradiol, and reported
declines in fathead minnow population size corresponding with
signs of reduced fecundity. However, while there is every expecta-
tion that decreased recruitment can decrease population size,
many other variables also can affect population status (Kramer
et al., 2011).
Overall, although the biological plausibility of the linkage
between fecundity and population status for this AOP is strong
(and there is some ﬁeld evidence to support this), in the absence
of additional empirical dose-response and time-course data, the
WoE for KER7 is considered only to be moderate.
3.1.3. Evaluation of WoE for entire AOP (aromatase inhibition leading
to reproductive dysfunction (in ﬁsh))
As noted in the OECD AOP Handbook (OECD, 2014a), WoE rank-
ings for the individual KERs will heavily inﬂuence the overall WoE
analysis for the entire AOP. However, there are components of the
WoE analysis (e.g., essentiality) that are most amenable for assess-
ment when considering the KEs (and associated relationships) in
the context of the whole AOP. Further, some facets of other WoE
considerations and associated guidance itself (OECD, 2014a)
become apparent only when evaluating the entire AOP. For exam-
ple, when evaluating the whole AOP, it is possible to assess rela-
tionships between KEs that are not immediately adjacent to one
another, denoted as indirect KERs (OECD, 2014a), which can be
important in the development of quantitative AOPs (in prepara-
tion, see Perkins et al. (in preparation), https://aopkb.org/
saop/workshops/somma.html). Below we describe an analysis for
the entire aromatase inhibition-reproductive dysfunction AOP,
conducted using the considerations summarized by OECD
(2014a). It should be noted that, due to space limitations, this eval-
uation is meant to be illustrative rather than exhaustive, so only a
comparatively small subset of available literature/data supporting
different aspects of the AOP are utilized.
Biological plausibility of the AOP is, as a whole, considered
strong. Based on knowledge derived from literally hundreds of
studies concerning normal ﬁsh reproductive endocrinology and
population dynamics published in the open literature (and sum-
marized in text books such as Norris and Carr (2013)), the cas-
cade of events depicted in Fig. 2 is both plausible and well
documented. Further, based on comparative endocrinology
research, it is highly probable that this AOP has a broad domain
of applicability in terms of its relevance, at least to ﬁsh species,
if not other oviparous vertebrates (Celander et al., 2011; Norris
and Carr, 2013).
Overall, based on studies with multiple chemicals, sampling
times, and ﬁsh species, empirical support of this AOP is judged to
be strong. There are extensive empirical data in support of the
overall AOP. Several studies with known CYP19 inhibitors (both
drugs and pesticides) have demonstrated a dose-dependent rela-
tionship between one or more of the KEs in the AOP and impacts
on fecundity. For example:
(1) In 21-day fathead minnow reproduction studies with fadro-
zole, prochloraz, and propiconazole, dose-dependent
decreases in plasma E2 were associated with corresponding
depressions in plasma VTG in females, and subsequent
decreases in fecundity (Ankley et al., 2002, 2005; Skolness
et al., 2013).(2) Both dose-dependency and consistency of the AOP in an
additional ﬁsh species were demonstrated in work with
the Japanese medaka (Oryzias latipes) in 21-day studies with
letrozole, a pharmaceutical speciﬁcally designed to inhibit
CYP19 (Sun et al., 2007). In those studies, decreases in
plasma VTG concentrations in females corresponded, in a
dose-dependent manner, with depressed egg production in
the ﬁsh and the decreases in VTG occurred at doses equal
to or greater than doses which depressed egg production.
(3) There also are empirical linked temporal-dose data support-
ing the aromatase inhibition-reproductive dysfunction AOP
in ﬁsh. For example, Villeneuve et al. (2009) and Ankley
et al. (2009b) described experiments with fadrozole and
prochloraz, respectively, in which fathead minnows were
exposed to two concentrations of the CYP19 inhibitors and
sampled at multiple times after exposure was initiated.
Although only a subset of the KEs was measured, results
observed were nonetheless consistent with the proposed
AOP.
Speciﬁcally, in exposed females, depressions in ovarian produc-
tion of E2 preceded decreased plasma levels of E2, which preceded
decreased plasma VTG concentrations. Further, this set of relation-
ships reﬂected the concentration of the chemical (fadrozole or
prochloraz) to which the ﬁsh were exposed, with responses occur-
ring more quickly and to a relatively larger degree in the high- ver-
sus low-dose treatment groups (Villeneuve et al., 2009; Ankley
et al., 2009b).
A potentially critical component of the WoE analysis for an
overall AOP involves evaluation of the concept of essentiality, i.e.,
demonstration that if a KE (which could include the MIE) in an
AOP is blocked in some manner, downstream KEs including the
AO do not occur. This type of evidence can be generated using
chemical inhibitors of upstream KEs or, in some cases, knockout
animal models that have been genetically-modiﬁed such that a
functional component of the pathway of interest is lacking.
Essentiality also can be demonstrated by reversibility of an impact,
i.e., when the chemical stressor impacting an upstream event is
removed, subsequent KEs recover.
Evidence of essentiality for the aromatase inhibition-
reproductive dysfunction AOP arises both from recovery studies,
and from a somewhat novel example of reversibility related to bio-
logical compensation/adaptation. The multiple time-point/dose
study design described above (Villeneuve et al., 2009; Ankley
et al., 2009b; Ankley and Villeneuve, 2015) included a recovery
phase where the fathead minnows were sampled for a period of
time after the chemical exposures were stopped. In those studies,
measurements of KEs in ﬁsh subsequently held in clean water after
the chemical exposures ended exhibited temporal relationships
consistent with the proposed AOP, i.e., depressed ovarian synthesis
of E2 recovered (increased) ﬁrst, followed by plasma E2 concentra-
tions, and then plasma VTG levels. Somewhat unexpectedly, how-
ever, there was additional evidence for essentiality of these AOP
KEs during the actual chemical exposure. Speciﬁcally ﬁsh, most
often in the low dose group, after an initial depression in synthesis
and plasma concentrations of E2, exhibited compensatory-type
responses that also reﬂected the anticipated temporal relation-
ships reﬂected in the AOP, e.g., increases in ovarian synthesis of
E2 preceded recovery of plasma E2 concentrations. This compen-
satory response appeared to be due to the up-regulation of key
steriodogenic enzymes (including CYP19) in the ﬁsh due to nega-
tive feedback within the hypothalamic-pituitary-gonadal axis.
Notably, similar time-course/dose-response studies with other
sex steroid synthesis inhibitors in the fathead minnow have pro-
duced compensation and recovery patterns analogous to the fadro-
zole and prochloraz work (e.g., Ankley and Villeneuve, 2015).
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between early KEs in the AOP in the context both of recovery
and compensation provide powerful support of essentiality. What
is lacking in the literature is extension of analysis of compensa-
tion/recovery to later KEs in the AOP, most notably the AO of
fecundity decreases.
Overall, based onWoE rankings of the individual KERs (Table 2),
and the WoE for the entire pathway, the aromatase-inhibition
reproductive dysfunction AOP (Fig. 2) is considered strong,
although uncertainties remain in terms of prediction of
population-level responses. This arises more from a lack of data,
rather than contradictory evidence of a disconnection between
fecundity and population size. Consequently, from a practical per-
spective in terms of the WoE relative to uncertainty, this AOP
would be judged as strong for the AO of fecundity decreases and
moderate for the AO of population-level effects. However, it could
be argued that this uncertainty is more quantitative than qualita-
tive, as it is obvious that if there is no reproduction, in the absence
of emigration, population extinction will occur.4. Lessons learned in applying the evolved WoE framework
During the discussions at the workshop, considerable focus was
given to clarifying the descriptors to guide decision making for
assigning conﬁdence in components of WoE for KEs, KERs and
the overall AOP. The workgroup also contributed to clariﬁcation
of terminology in development of the OECD Users’ Handbook.
The ‘‘lessons learned’’ based on the experience of the workgroup
in discussions and during the development and analysis of the
diverse set of the case examples (see Annex) are articulated below,
both in recognition that evolution is informed principally by prac-
tical application and to aid others who are embarking on documen-
tation of WoE evaluation of AOPs. For a more complete picture of
the evolution of AOP development and current thinking on applica-
tion to integrated approaches to testing and assessment, readers
should consult the companion publications stemming from the
Somma Lombardo workshop: Garcia-Reyero (2015), Groh et al.
(2015a,b), Tollefsen et al. (2014), Villeneuve et al. (2014a,b), and
Perkins et al. (in preparation) (see https://aopkb.org/saop/work-
shops/somma.html).4.1. The need to focus on KERs
The evolved WoE framework illustrated in Table 1 (and
expanded in the OECD AOP Handbook (OECD, 2014a)) clariﬁes
the need for considering both KEs and KERs in addressing WoE
for AOPs, with essentiality relating to KEs (within the context of
the AOP) and biological plausibility and empirical support relating
to KERs. As the framework evolved and discussions proceeded, the
emphasis relevant to consideration of WoE in relation to intended
uses of AOPs increased focus on understanding and deﬁning
KEupstream so as to enable prediction of KEdownstream using results
of assays that measure KEupstream and suitable prediction models.
For example, one may wish to use results of the KEs measured with
in vitro assays of receptor binding and transcriptional activation in
an estrogen pathway to predict in vivo responses of the utero-
trophic assay (Rotroff et al., 2013), an in vivo Tier 1 screening assay
in the USEPA Endocrine Disruptor Screening Program. To do so,
requires a predictive relationship that uses results of the KEs of
binding and transactivation as the input to a model, whose output
is the estimated response in the uterotrophic assay. While the
overall AOP represents the sequence of KEs, it is the KERs which
characterize the relationships between KEs, and in essence, such
relationships are qualitative or quantitative prediction models.
Hence, in the current framework, distinction of variouscomponents of KERs, which encompass knowledge of KEupstream
and KEdownstream , the understanding of the relationship (the ability
to predict KEdownstream from KEupstream) between KEs has been made
more explicit. Capturing the evidence for causality at the level of
each KER provides two additional advantages. First, it promotes a
systematic approach to the evaluation and recording of the evi-
dence by directing the author to consider each link in the chain
before evaluating the overall AOP. Second, it facilitates the reuse
of the evidence in other AOPs for which the speciﬁc KER is a com-
ponent thereby promoting consistency and completeness in
describing all AOPs.
4.2. Biological plausibility of KEs and KERs
For evaluating biological plausibility, emphasis is placed on the
biological basis of the AOP and its KEs and KERs. The initial impulse
of most scientists to questions of biological plausibility of the KEs
and KERs within an AOP is to look to experimental evidence to
make a cogent case. In particular, there is a predilection for toxicol-
ogists to review and cite experimental evidence of dose response,
effects and outcomes of chemical exposure when undertaking
the WoE evaluation for all three elements of the AOP WoE frame-
work (biological plausibility, essentiality and empirical evidence).
This initial experience within the workshop contributed to evolu-
tion of the deﬁning questions and the descriptors to guide decision
making for assigning level of evidence. The interactions between
experts in human health and experts in environmental and ecotox-
icology were particularly valuable.
In addressing the deﬁning question in the OECD AOP Handbook
summary table template (e.g., Table 1) to determine the WoE of
biological plausibility of an AOP, focus needs to be placed on eval-
uating the extent to which the AOP aligns with current under-
standing of normal physiology, biological processes and
pathways of pathogenesis culminating with adverse effects. In
other words, characterizing the extent to which the scientiﬁc com-
munity has accepted an established mechanistic basis for the steps
in the pathway. The AOP developer should explicitly address the
understanding of the biology, i.e., the degree of knowledge and
extent of scientiﬁc acceptance of the biological steps and sequence
in the AOP. Although the foundation in part for such acceptance
will be empirical evidence, the rationale for plausibility should
focus on biological pathways and relationships of KEs; detailed
analysis of dose response results is conducted in the empirical evi-
dence evaluation step. Since the AOP is describing the biological
basis for the adverse outcome (AO), information from
non-chemical perturbations can also be used in establishing the
biological plausibility. For example, knockout mouse models that
block a speciﬁc KE can establish both the causal relationships nec-
essary for biological plausibility as well as the essentiality of the KE
as described below.
Increasingly, biological plausibility is being limited to extent of
understanding/acceptance of the biology to distinguish it from
essentiality of key events. While the overlap is recognized, to some
degree, this is a function more of ‘‘codifying’’ WoE considerations
to simplify and increase common understanding.
4.3. Essentiality of the KEs within the AOP
As was the case for biological plausibility, the initial discussion
of the workgroup at the workshop tended to focus on reviewing
and citing experimental evidence of dose response and temporal
concordance (i.e., empirical support) to evaluate essentiality, e.g.,
making the case that KEdownstream is essential, as indicated by the
fact that there is a dose dependent change in KEdownstream as a
result of the dose response of KEupstream. It became clear that to bet-
ter differentiate essentiality from empirical evidence, and to more
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need to more explicitly clarify the nature of supporting data and
descriptors guiding determination of the level of evidence associ-
ated with high, moderate and low conﬁdence.
For essentiality, as reported in Meek et al. (2014b), the most
persuasive evidence is when the KEdownstream is not observed when
KEupstream is blocked. Going into the workshop, studies that demon-
strate reversibility (e.g., stop or recovery experiments,) were iden-
tiﬁed as the sort of evidence that provides a high degree of
certainty regarding essentiality. During the workshop, participants
pointed out that in pharmacology, the use of an antagonist to block
the response elicited by an agonist is a classical method for estab-
lishing essentiality. In addition to classical pharmacological antag-
onism, evidence from genetically engineered models (e.g.,
knockout, knock-in, conditional gene modiﬁcations, etc.) can pro-
vide a high degree of speciﬁcity and certainty regarding essential-
ity. The OECD AOP Handbook workgroup determined that indirect
evidence, in particular, modulation of a KE by a factor that attenu-
ates or augments the response is also useful, and should be viewed
as providing a moderate degree of certainty for essentiality. In the
developing discussion of the components of WoE, it was also clar-
iﬁed that since essentiality of the KEs relates to prevention or
attenuation of any downstream key event when an upstream key
event is blocked or modiﬁed, it is most readily assessed in the con-
text of the entire AOP, rather than individual KERs.
In an ideal case, data would be available to allow evaluation of
the essentiality of each and every KE. However, this would require
an enormous amount of experimental evidence. From a practical
perspective, experience has shown that essentiality data typically
focus on one or a limited set of KEs. Thus, in evaluating essentiality,
the determination is made for the overall AOP. For example, to
demonstrate the essentiality of the KE of translation to the overall
AOP, cycloheximide could be used to block protein synthesis. For
AOPs focused on tumorigenesis, stop exposure studies in cancer
bioassays and initiation promotion studies can also provide evi-
dence of essentiality of a KE to the overall AOP.4.4. Empirical support
The case examples emphasized the importance of separating
empirical support from biological plausibility and its lesser weight-
ing in contributing to WoE; experience gained was particularly
critical in this context since empirical support is normally demon-
strated in studies with different types of stressors. Application of
the guidance to the case examples was also helpful in increasing
understanding that empirical support relates to ‘‘concordance’’ of
dose response, temporal, and incidence relationships for KERs
rather than the KEs. Although the initial focus was on whether or
not there was a dose-response relationship for a deﬁned key event,
the emphasis was shifted to reviewing and citing experimental evi-
dence of agreement in dose response and temporality among key
events (i.e., concordance), which is demonstrated based on studies
with administered stressors. For dose response, this would be
determination that the KER reﬂects dose-dependent changes in
KEdownstream as a result of the dose response of KEupstream. For tem-
porality, demonstration that KEupstream precedes KEdownstream was
expanded to include evidence that KEupstream occurs at lower doses,
at earlier time points and at higher incidence than KEdownstream. For
concordance, there was agreement that the strongest degree of
certainty arises from multiple studies in relevant test systems
(i.e., orthogonal methods) which show similar qualitative/quanti-
tative responses. The OECD AOP Handbook contributors further
reﬁned the questions and evidence descriptors, and importantly,
provided greater granularity to the descriptors for M and L evi-
dence descriptors.The contribution of the tabulation of temporal, dose-response
and incidence data, in a format to identify relevant trends identi-
ﬁed in the Guidance was also recognized and recommended in
the OECD AOP Handbook (OECD, 2014a). Although beyond the
scope of the purpose and intent of the case example summaries
presented here, it is acknowledged that standardized presentation
in tabular format has the potential to simplify considerably the
review of supporting evidence to support WoE determinations
for AOPs.
4.5. Inconsistencies and uncertainties
One of the key lessons learned for those developing or evaluat-
ing AOPs is that uncertainties and inconsistencies need to be
explicitly considered and integrated as part of the determination
for each element of the three recommended BH considerations:
biological plausibility, essentiality and empirical evidence.
Originally, WoE guidance from OECD included a separate element
to address uncertainties and inconsistencies, and this element was
initially carried through in the evaluation of the case examples pre-
sented here. However, even at that time it was recognized that this
was largely redundant, in that inconsistencies and uncertainties
were implicitly already factored into the evaluations of each of
the other elements of the WoE framework as part of the process
for determining the degree of evidence (e.g., H, M or L).
Following the workshop, in the process of modifying the OECD
AOP Handbook, this lesson learned contributed to deletion of a
separate element for inconsistencies and uncertainties to avoid
redundancy.
4.6. The role of chemical-speciﬁc case example AOPs
There is a dynamic tension in developing AOPs between the
need to rely on, and use, experimental evidence and knowledge
derived from speciﬁc chemicals and the need to construct an
AOP such that it focuses on the biological steps and pathways, in
a manner that is agnostic to a speciﬁc chemical (Villeneuve et al.,
2014a). For well characterized pathways and MoAs, it may be
easier to refrain from over reliance on a speciﬁc chemical. But, rec-
ognizing that this will not always be the case in terms of available
data, and in order to foster AOP development, including develop-
ment of more speculative AOPs, it is acceptable within the OECD
AOP program to propose either of two types of AOPs: (1) those
with an MIE that could be affected by a variety of chemicals, and
(2) those applicable to a single chemical or a very limited number
of chemicals (OECD, 2014a). For such chemical-speciﬁc case exam-
ples, the WoE evaluation will typically be limited to a speciﬁc MoA
analysis of a single chemical. With time and with additional input
(e.g., additional data and analyses encompassing a broader domain
of chemistries) the breadth of application of these
chemical-speciﬁc case example AOPs could expand.
4.7. Consideration of non-adjacent KERs
As discussed in the OECD AOP Handbook (OECD, 2014a), an
indirect KER is one that links a pair of non-sequential KEs. For
example, if there is uncertainty or difﬁculty in measuring KEn+1,
one could use an indirect KER that links the upstream KEn to the
downstream KEn+2. In other words there may be sufﬁcient data
to establish the KEn+1 as part of the AOP, but to evaluate the
WoE of the AOP one may have to rely on the indirect KER by ‘‘leap-
ing over’’ KEn+1. When evaluating indirect KERs, the WoE for these
relationships should be explicitly described and knowledge gaps
communicated. This will help those interested in applying the
AOP for a speciﬁc use to ascertain whether measures of responses
at KEn can be used to predict downstream KEs (including the AO),
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uncertainty is too great to support bypassing KEn+1. Such decisions
will clearly depend upon the intended use of the AOP; for example,
we expect that certain uses, such as priority setting, may have a
tolerance for greater uncertainty than other regulatory
applications.4.8. Challenges in presenting and communicating WoE rationales
The analyses conducted to illustrate application of the WoE
approach for the case example AOPs highlight the difﬁculties
encountered when trying to condense and summarize considerable
quantities of scientiﬁc evidence, often of varying quality and devel-
oped for diverse purposes, into succinct lines of evidence which
align with the three BH considerations of biological plausibility,
essentiality and empirical evidence. One element that was not dis-
cussed here, but that is addressed elsewhere and is relevant to
establishing scientiﬁc conﬁdence in an AOP, is the issue of test
method validity with respect to data quality and reliability.
Although regulatory testing under the auspices of OECD or EPA test
guidelines employs validated methods, much of the data that will
be used in constructing AOPs will be based on non-guideline meth-
ods, and OECD has developed draft guidance (OECD, 2014c) to aid
developers and reviewers to evaluate the quality of data produced
by such methods. Cox et al. (2014) also discuss an approach to, and
the importance of, evaluating the analytical performance of assays
used to measure KEs and prediction models (e.g., qualitative or
quantitative KERs) and communicating the scientiﬁc rationale
explaining the conﬁdence in use of the KER for a ﬁt for purpose
application. Moving forward, use of the summary table template
in Annex 1 of the OECD AOP Handbook (OECD, 2014a) should help
to improve presentation and communication of the evidence
underpinning the H, M, L designations for the WoE for each of
the three recommended BH considerations. As more experience
is gained it is expected that this too will contribute to continued
reﬁnement overall. The recent development of the AOP ‘‘alkylation
of DNA in male pre-meiotic germ cells leading to heritable mutations’’
by Yauk et al. (2015), which was also used in an iterative process to
further test and reﬁne the OECD AOP Handbook in its entirety, pro-
vides an example of an in-depth analysis of a data rich AOP. This
AOP clearly illustrates enhanced transparency that is required in
presenting supporting data and evaluation of WoE based on les-
sons learned and the continuing efforts under the OECD AOP
Programme and supporting initiatives.5. Looking ahead: quantitativeWoE evaluation – challenges and
opportunities
Weight-of-evidence evaluation involves a diverse set of meth-
ods. Transparency and reproducibility of the results are increas-
ingly important areas of concern within the scientiﬁc
community, though achieving these objectives is challenging.
Although the OECD AOP Handbook (OECD, 2014a) provides guid-
ance for improved transparency and enhances communication of
the rationales for arriving at H, M or L determinations in WoE eval-
uations of AOPs, reproducibility remains a challenge. The qualita-
tive WoE logic method recommended in the OECD AOP
Handbook may be useful for simple AOPs. However, qualitative
methods are limited by the inability to easily deal with complex
datasets where multiple criteria and metrics make it difﬁcult to
develop a narrative that integrates multiple logical constructs
together. Consequently, a quantitative approach for AOPWoE eval-
uation using multi-criteria decision analysis (MCDA) (Linkov et al.,
2009; Perkins et al., in preparation) holds considerable promise.Quantitative WoE methods require developing criteria (through
which experts judge the importance of individual lines of evi-
dence) and metrics (used to measure the performance on criteria),
through which alternatives are evaluated (Linkov et al., 2009,
Linkov and Moberg, 2012). In MCDA, criteria, metric weights, and
scores are used to represent either objective data or the subjective
preference values of decision makers with respect to decision
goals. Weights are assigned to criteria and metrics based on their
relative importance for the ultimate evaluation goals and individ-
ual lines of evidence are subsequently scored based on their rela-
tive performance on these criteria and metrics. The weights and
scores are then synthesized using different mathematical or statis-
tical models to form an overall conclusion. Quantitative WoE
methods can be based on individual judgment or group decision
process.
In the context of AOPs, advanced quantitative methods such as
MCDA and Bayesian Network analysis are especially useful. The
evolution of the BH considerations for WoE for MoA and AOPs
(Table 1) reﬂects the order of relative importance of each consider-
ation (e.g., biological plausibility > essentiality > empirical evi-
dence) and for each consideration, the degree of conﬁdence in
KERs (i.e., H, M, or L). This hierarchical approach lends itself to
decision modeling and quantitative scoring, wherein the overall
WoE can be calculated as integrative metrics of weights associated
with the BH considerations and their associated KER conﬁdence
levels.
For illustration purposes, we developed a prototype quantita-
tive MCDA model (Fig. 3) for the AOP of aromatase inhibition lead-
ing to reproductive dysfunction in ﬁsh (described above). The
MCDA model description generated for the quantitative WoE eval-
uation of this AOP are presented in the Supplementary Material.
Input was provided by expert elicitation from two leading experts
involved in the development of this AOP. DECERNS software
(Linkov and Moberg, 2012) was used for the analysis, and the sup-
plementary ﬁgures presented are direct outputs of the DECERNS
Software.
It is important to note that the purpose of the following discus-
sion is to be illustrative only and should be taken as a prototypical
demonstration of MCDA applied to WoE for an AOP; the quantita-
tive scores are not to be used in any manner that would suggest
they are deﬁnitive. The quantitative MCDA model was constructed
using the three evolved BH considerations (biological plausibility,
essentiality and empirical evidence), their relative importance
(biological plausibility > essentiality > empirical evidence), and
the scores of H, M and L, evaluated through deﬁning questions
evaluated through the deﬁning questions (Table 1). The model
allows for evaluation of relative strength of evidence underpinning
KEs and KERs within this AOP and follows the logic set forth in the
OECD AOP Handbook and theWoE summary table template (OECD,
2014a).
The ranking of KERs is shown in Fig. 4. This prototype MCDA
model shows that the highest WoE conﬁdence is in KER1 (aro-
matase inhibition leading to reduced E2 synthesis) and KER2,
(reduced E2 synthesis leading to reduced plasma E2). The lowest
WoE conﬁdence is found to be in KER6 (reduced oocyte growth
leading to reduced fecundity).
A quantitative WoE approach such as MCDA allows for incorpo-
ration of inputs from multiple experts, strengthens WoE logic con-
structs by adding the visual effect of a mapped decision structure,
includes quantitative weighing of individual lines of evidence, and
allows for sensitivity analysis. Exploration of the sensitivity of the
WoE for each KER to changes in weighting schemes is illustrated in
the Supplementary Material. Such a sensitivity analysis can be
used in a value of information analysis and play an important role
in delineating additional research areas where developing a greater
Fig. 4. Scores for conﬁdence assessment in each KER of the aromatase inhibition AOP. Each KER contains an overall score from 0 to 1 that is a cumulative score originating
from individual scores for all criteria.
Fig. 3. Prototype MCDA model for quantitative WoE determination for KERs in the aromatase AOP.
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on improving the overall conﬁdence in the AOP.6. Conclusions
There are a large number of possibilities for using the WoE con-
ﬁdence levels for KEs and KERs and AOPs. At the workshop, and insubsequent follow up discussions, approaches to combining the
hierarchical weighting of the three BH considerations with the
individual conﬁdence weightings for each KER to arrive at an over-
all conclusion about the conﬁdence level of the overall AOP were
considered. As illustrated, MCDA can be used to construct a quan-
titative model for accomplishing this. However, at this early stage
of WoE evaluations of AOPs, we recommend that AOP developers
conduct a point-by-point qualitative evaluation of the overall
R.A. Becker et al. / Regulatory Toxicology and Pharmacology 72 (2015) 514–537 525AOP that is supported by the summary table, and also consider
including a written narrative rationale in terms of overall level of
conﬁdence (i.e., H, M or L) in the AOP. We also recommend that this
rationale be uploaded into the AOP-Wiki, to ensure transparency
and promote collaborative discussions across both the regulatory
and scientiﬁc community. Once experts have gained adequate
experience in applying evolved BH considerations to AOPs, and
likely not in the too distant future, it will be feasible to organize
a consensus expert elicitation process to reﬁne quantitative
MCDA application to AOP WoE determinations.
It is important to note that there will likely be cases where the
overall conﬁdence in using a KE or KER to predict the AO would be
low. Nevertheless the conﬁdence in speciﬁc KEs or KERs may be
sufﬁcient to use for a particular assessment application. For exam-
ple, the MIE or an early KER may be known with sufﬁcient cer-
tainty that assays for these could be used for purposes of priority
setting or read across even when the knowledge of the quantitative
predictivity of these KEs for the AO may be too uncertain for use in
hazard identiﬁcation or risk assessment purposes. In the AOP-Wiki,
the WoE documentation provides degree of conﬁdence in KERs
that can assist with such decisions; the network view illustrates
the degree of conﬁdence graphically by the weight of the arrows
linking KEs.
The quantitative MCDA prototype illustrated here holds consid-
erable promise to enhance the rigor, transparency and repro-
ducibility for AOP WoE determinations. Compared to a
qualitative approach, a MCDA approach enables more precise,
transparent and explicit delineation of expert judgment. Even
though deﬁning criteria and metrics for speciﬁc AOPs can be rela-
tively easy, reliable scoring and weighting may be quite challeng-
ing. A meaningful correlation of expert-driven weighting and
scoring will require signiﬁcant efforts from the expert community
(Linkov et al., 2015).Transparency Document
The Transparency document associated with this article can be
found in the online version.Acknowledgments
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Annex: Case Examples
List of abbreviations for Annex
TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin
AO adverse outcome
AOPs adverse outcome pathways
ARNT AhR nuclear translocator
AhR arylhydrocarbon receptor
CYP cytochrome P450
ER estrogen receptor
ERa estrogen receptor a
CrVI hexavalent chromium
JH juvenile hormone
KE key event
KERs key event relationships
Met methoprene-tolerant
MOA modes of action
MIE molecular initiating event
NADPH nicotinamide adenine dinucleotide phosphate, reduced
NTP National Toxicology Program
NTE neuropathy target esterase
OPIDN OP-induced delayed neuropathy
OECD Organization for Economic Co-operation and Develop-
ment
OPs organophosphates
PHAHs polyhalogenated aromatic hydrocarbons
PAHs polyaromatic hydrocarbons
ROS reaction oxygen species
SDD sodium dichromate dihydrate
SRC steroid receptor coactivator
TA transit amplifying
TOCP tri-ortho-cresyl phosphate
US EPA US Environmental Protection Agency
WoE weight of evidence
XRE xenobiotic response elements
A.1. Case example: arylhydrocarbon receptor (AhR) activation
(MIE) leading to induction of cytochrome P450 CYP)
monooxygenases (KE1) and oxidative stress (KE2): evaluation of
a subset of KEs and KERs
A number of xenobiotics, including polyaromatic halogenated
hydrocarbons (PHAHs) such as 2,3,7,8-tetrachlorodiben
R.A. Becker et al. / Regulatory Toxicology and Pharmacology 72 (2015) 514–537 527zo-p-dioxin (TCDD), and polyaromatic hydrocarbons (PAHs) such
as benzo(y)pyrene, act as agonists of the arylhydrocarbon receptor
(AhR). The ligand–receptor complex translocates to the nucleus
and dimerizes with the AhR nuclear translocator (ARNT). The
AhR/ARNT dimer binds to xenobiotic response elements (XRE) of
genes and thereby activates their transcription. The AhR pathway
regulates a battery of genes, including several cytochrome P450
monooxygenases, notably those of the CYP1A family (CYP1A1,
CYP1A2, CYP1B1). Xenobiotic activation of the AhR pathway can
be associated with the production of oxidative stress which is con-
sidered to play a major role in the toxicity of AhR-binding chemi-
cals, in particular in causing mutagenicity and tumour formation.
The term oxidative stress refers to any shift of the cellular redox
homeostasis towards the increased production of reaction oxygen
species (ROS) relative to the cellular antioxidant defence.
Here, we discuss an AOP linking AhR activation to tumor forma-
tion. For illustrative purposes (Fig. A1), we focus only on the fol-
lowing steps: the MIE which is xenobiotic binding to and
activation of the AhR, the subsequent induction of CYP enzymes
(KE1), and the induction of an oxidative stress response (KE2).A.1.1. Biological plausibility (AhR induction of cytochrome CYP
monooxygenases leading to oxidative stress)
There exists a well-conﬁrmed mechanistic relationship
between the MIE (AhR activation) and KE1 (CYP monooxygenase
induction) (Beischlag et al., 2008). A plausible mechanism exists
also for the induction of oxidative stress by CYP monooxygenase
activity. In the course of the reaction catalyzed by CYP monooxyge-
nases, two electrons are sequentially transferred from
NADPH-dependent cytochrome P450 oxidoreductase to each atom
of bound oxygen, resulting in the production of oxygenated sub-
strate and water. Although tight coupling normally exists between
oxygen reduction and monooxygenation, some reactive oxygen
may be released as either superoxide or H2O2 in the course of the
electron transfer. In this way, CYP monooxygenases can produce
ROS (Dalton et al., 2002; Reichard et al., 2006), with the rate of
CYP-dependent ROS generation depending on the efﬁciency – or
inefﬁciency – of the coupling of NADPH consumption to substrate
oxidation (Schlezinger et al., 1999; Zangar et al., 2004). In fact, the
ability of CYP-containing microsomes for NADPH-dependent gener-
ation of ROS has been known for over 50 years (Gillette et al., 1957).
Importantly, however, mechanisms other than monooxygenase-
dependent ROS production can lead from AhR activation to oxidative
stress. One possible mechanism is that CYP1A-catalyzed metabolism
produces oxidative stress not by direct ROS generation, but indi-
rectly via generation of reactive metabolites. For instance, it is
known that female rats are more susceptible to TCDD-induced
oxidative stress than males (Dalton et al., 2002). The causativeFig. A1. Depiction of a subset of KEs and KERs relating arylhydrocarbon receptor (AhR) ac
stress.mechanism involves, at least in part, monooxygenase-catalyzed
metabolism of estrogen. Since TCDD affects the activity of CYP
monooxygenases, it can thereby alter the production and the ratios
of electrophilic metabolites of estradiol such as the hydroxy-E2
catechols, which in turn alter the cellular oxidation status
(Dalton et al., 2002). Another possible mechanism is the
AhR-regulated reduction of the cellular antioxidant capacity, for
instance, by induction of cytoprotective genes such as
NAD(P)H:quinone oxidoreductase 1, glutathione-S-transferases
and UDP glucuronosyltransferases, which combat oxidative stress
(Latchoumycandane et al., 2002; Kalthoff et al., 2010). This latter
mechanism involves a crosstalk between the AhR and another
transcription factor, the nuclear factor erythroid 2-related factor
(nrf2) (Lu et al., 2011). Another CYP-independent mechanism of
oxidative stress production by AhR ligands seems to be the induc-
tion of cytokines (Nebert et al., 2000; Tsuji et al., 2011). Finally,
there exists evidence that dioxins can induce mitochondrial ROS
production by a mechanism independent of CYP monooxygenase
activity (Senft et al., 2002). Thus, in all likelihood, there are several
AhR-dependent pathways that lead to oxidative stress, involving
both an increase of monooxygenase-dependent ROS production
as well as other pathways (Dalton et al., 2002).A.1.2. Essentiality (AhR induction of CYP monooxygenases leading to
oxidative stress)
Evidence shows that KE1 can be prevented by blockage of AhR
binding as well as in AhR knockout animals; thus, AhR activation is
essential for induction of monooxygenases such as CYP1A
(Beischlag et al., 2008). The situation is less clear for the relation
between CYP monooxygenase activity and ROS production. Kopf
et al. (2010) showed that CYP1A knockout mice accumulated
TCDD at similar levels as wild type mice, but in contrast to wild
type mice, did not show ROS production. Related to this is the
observation that toxicological sensitivity to TCDD differs between
ahr/ and cyp1a/ mice (Reichard et al., 2006); knockout of
CYP1A protected the mice against TCDD doses up to 200 lg/kg,
whereas AhR knockout protected against TCDD doses up to
2 mg/kg. Another interesting observation concerning the relation-
ship between AhR, CYP monooxygenases and ROS is that
TCDD-exposed cyp1a/ could produce mitochondrial ROS despite
the absence of CYP1A. This ﬁnding supports the hypothesis that
CYP1A induction is not essential for AhR-dependent ROS produc-
tion in the mitochondria. Furthermore, the ﬁnding that ahr/ mice
were not capable of mitochondrial ROS production after TCDD
exposure (Senft et al., 2002) points to the essentiality of AhR acti-
vation. Overall, the available data, although fragmented, point to
an essential role of AhR in ROS generation and oxidative stress,
while the essentiality of CYP1A appears to be moderate at best.tivation to the induction of cytochrome P450 ( CYP) monooxygenases and oxidative
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leading to oxidative stress)
Numerous studies report that activation of the AhR pathway is
associated with oxidative stress. As shown by Schlezinger and
Stegeman (2001) for the teleost species, Stenotomus chrysops, there
exists a signiﬁcant correlation between the level of microsomal
CYP1A activity and the microsomal rate of ROS production.
Pronounced and prolonged induction of oxidative stress has been
shown to occur in humans and rodents after exposure to
AhR-binding PHAHs and PAHs (Shertzer et al., 1998; Slezak et al.,
2000; Dalton et al., 2002; Reichard et al., 2006; Costa et al.,
2010; Tsuji et al., 2011). ROS production after TCDD exposure is
signiﬁcantly higher in C57BL/6 mice, which carry the
high-afﬁnity ahrb1 allele, compared to the low-afﬁnity DBA/2 mice
(Alsharif et al., 1994). Induction of oxidative stress by AhR-binding
xenobiotics has also been shown in ﬁsh (Palace et al., 1996;
Schlezinger and Stegeman, 2001). Dose- and time-dependent rela-
tionships between AhR ligand exposure and ROS production can be
complex: for instance, in mice, higher tissue concentrations of
TCDD were required to elicit oxidative stress responses following
acute exposure than with subchonic exposure (Reichard et al.,
2006). This may relate to adaptive/compensatory processes which
inﬂuence dose– as well as time–response relationships so that in
many cases KEupstream does not linearly translate into KEdownstream.
The pathway from the MIE to oxidative stress involves two KERs.
For KER1, extensive empirical evidence supports a direct, both dose-
and time-dependent linkage between AhR activation and CYP
monooxygenase gene expression (Beischlag et al., 2008). Also for
KER2, good empirical evidence exists for different animal taxa that
elevated CYP monooxygenase activity associates with oxidative
stress (Dalton et al., 2002; Curtis et al., 2011). A well-studied exam-
ple that AhR-mediated induction of CYP monooxygenases results in
the production of oxidative stress comes from studies on the effect of
dioxins on vascular endothelia (Kopf and Walker, 2010).
A.1.4. WoE conclusions (AhR induction of cytochrome P450 enzymes
leading to oxidative stress)
Based on considerations described above, the WoE for KER1 is
strong. The relation between KE1 and KE2, however, is more equiv-
ocal. There is clear evidence that in many cases AhR-mediated
increase of CYP monooxygenase activity (in particular of CYP1A)
results via increased ROS production in the production of oxidative
stress; however, there also exist AhR-regulated but CYP-
independent pathways of oxidative stress production. The situa-
tion becomes even more complicated if we do not consider the
relation between CYP and ROS, but between CYP and oxidative
stress. AhR-induced oxidative stress does not necessarily occur
via CYP monooxygenase activity and CYP-dependent ROS produc-
tion, but there exist alternative mechanisms linking AhR activation
to oxidative stress. Thus, based on considerations of essentiality
and empirical evidence, WoE for KER2 is only moderate.
A.2. Case example: juvenile hormone agonist-induction leading
to increase in male offspring in the arthropod cladocera:
evaluation of a subset of KEs and KERs
In the cladocera, commonly called water ﬂea including the
Daphnia species, juvenile hormone (JH) regulates important phys-
iological and developmental processes, such as molting, growth,
reproduction, and sex determination. Insects and other crustaceans
also use JHs with similar structure and various JH analogs (agonists)
have been developed for the control of insect growth. JH analogs,
such as pyriproxyfen, fenoxycarb and diofenolan, and also known
as insect growth regulators, have been reported to induce maleoffspring in the cladocera. The cladocera generally reproduce female
offspring by parthenogenesis; however, when the environmental
conditions worsen (short day length, food shortage, an increase in
population density), they produce male offspring and sexual repro-
duction occurs. Male offspring production by topical application of
crustacean JH (methyl farnesoate), insect JH (JHIII) and JH analogs
occurs independent of environmental conditions, suggesting that
JH is a key endocrine factor for sex differentiation working down-
stream of environmental stimuli in the cladocera (Olmstead and
LeBlanc, 2003; Tatarazako et al., 2003; Oda et al., 2005; Abe et al.,
2015). Therefore, identiﬁcation sex of offspring by the length of ﬁrst
antenna was added as the optional endpoint in D. magna reproduc-
tion test (OECD TG 211, annex 7) to evaluate JH action.
A pathway of sex determination/differentiation regulated by JH
has been gradually uncovered mainly in Daphnia species. As a MIE,
JH and its analogs interact with the JH receptor (a heterodimer of
Methoprene-tolerant (Met) and steroid receptor coactivator (SRC)
proteins (Miyakawa et al., 2013; LeBlanc et al., 2013). Activation
of the JH receptor with JH or JH agonists most likely induces
Doublesex1 gene expression (KE1) later on during ovarian develop-
ment, resulting in the male production (KE2) (Kato et al., 2011).
Increase of male population may lead to reduction of reproductive
rate in the population (AO) because sexual reproduction produces
only two female offspring from dominant eggs per brood (Fig. A2).
Currently, insufﬁcient direct evidence of the KER between JH
receptor binding by JH and its analogs (MIE) and activation of
Doublesex1 gene expression (KE1) is available since the
Doublesex1 gene has only been recently identiﬁed (Kato et al.,
2011). Therefore, we evaluate the indirect relationship between
JH receptor binding (MIE) and the increase in production of male
offspring (KE2) for purposes of the WoE analysis.
A.2.1. Biological plausibility (JH receptor binding by an agonist (MIE)
and increase in male offspring (KE2))
While several JH agonists (e.g. fenoxycarb, pyriproxyfen, metho-
prene, epofenonane and diofenolan), which induce male offspring
in several species of the cladocera in in vivo tests were reported to
bind to the JH receptor (Met and SRC Heterodimer), the understand-
ing of the downstream KEs after key gene expression (KE1) that
result in the production of male offspring is not complete, in partic-
ular KEs at the cellular and organ level. Thus, the biological plausibil-
ity between JH receptor binding by agonists and an increase in male
offspring production is considered moderate.
A.2.2. Essentiality (JH receptor binding by an agonist (MIE) and
increase in male offspring (KE2))
Essentiality of JH receptor binding is considered strong because
there is direct experimental evidence showing that transcriptional
knockdown of the JH receptor gene in Daphnia magna embryos
resulted in embryonic death (Miyakawa et al., 2013). In addition,
transcriptional knockdown of Doublesex1 gene in the male embryo
which was induced by exposure to fenoxycarb did not develop the
male phenotype, suggesting that Doublesex1 gene expression (KE1)
is essential for male offspring development (Kato et al., 2011).
A.2.3. Empirical support (JH receptor binding by an agonist (MIE) and
increase in male offspring (KE2))
JH receptor binding studies in D. magna and D. pulex which use a
two-hybrid assay (Miyakawa et al., 2013) and luciferase reporter gene
assays (LeBlanc et al., 2013) showed that transcriptional activation of
JH receptor by JH agonists in vitro occurs at lower concentrations than
those inducing male offspring in vivo (Tatarazako et al., 2003). With
respect to temporal concordance, production of male offspring is
Fig. A2. Depiction of the subset of KEs and KERs in the juvenile hormone agonist-induced increase in male offspring in the arthropod cladocera AOP.
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ovulation) (Kato et al., 2010), and expression of Doublesex1 gene is
up-regulated 18 h after ovulation in JH-exposed offspring (Kato
et al., 2011). This indicates that JH receptor binding (MIE), which is
probably followed by Doublesex1 gene expression (KE1), occurs in
the ﬁrst half period of embryo development in the brood chamber
after exposure of JH and JH analogs. Regarding the evaluation of con-
sistency,male offspring production by JHagonistswas observed in six
cladoceran species (Olmstead and LeBlanc, 2003; Toyota et al., 2013).
Accordingly, consistency across species is considered high (strong).
However, Miyakawa et al. (2013), reported a juvenoid (e.g. epofeno-
nane) inducedmale offspringwithout interaction ofMet and SRChet-
erodimer JH receptor. This suggests that there may be interactions
with other receptor(s) or other steps in the pathway (e.g. stimulation
of JH secretion) that are not yet well understood. As the focus of this
evaluation was on the liner pathway between JH receptor binding
andmale offspring production, this result is not considered empirical
evidence for inconsistencies of the KER. Therefore, empirical support
for the KER between MIE and KE2 is considered strong.
A.2.4. WoE conclusions (JH receptor binding by an agonist (MIE) and
increase in male offspring (KE2))
Based on moderate biological plausibility and strong essential-
ity and empirical support, overall WoE for the indirect KER
between JH receptor binding by an agonist and increase in male
offspring is considered strong.
A.3. Case example: binding of certain organophosphates to
neuropathy target esterase (NTE) leading to delayed
neuropathy: evaluation of a subset of KEs and KERs
A well-known chemically induced neuropathy is a cen-
tral/peripheral sensory-motor distal axonopathy that appears upto several weeks after exposure to certain organophosphates
(OPs), named OP-induced delayed neuropathy (OPIDN) (Abou
Donia and Lapadula, 1990; Weiner and Jortner, 1999). It is clear
that not all OPs can cause OPIDN. Selected OPs used in aviation ﬂu-
ids or as oil additives such as tri-ortho-cresyl phosphate (TOCP)
and insecticides like chlorpyrifos, dichlorvos, isofenphos,
methamidophos, mipafox and trichlorfon have been shown to
induce OPIDN in humans and animal models (Weiner and
Jortner, 1999; Lotti and Moretto, 2005). These OPIDN inducers
covalently bind to the active site of neuropathy target esterase
(NTE) (Johnson, 1990), causing not only inhibition but also ‘‘aging’’
of the enzyme, a process that is characterized by loss of an
R-group from the phosphoryl moiety that leads to the formation
of a negatively charged phosphoryl group, which is covalently
bonded to the active site serine of the esterase (Richardson
et al., 2013). The majority of experimental data derives from
adult hens (18 weeks old), the animal model of choice for the
identiﬁcation of OPIDN inducers (Doherty, 2006). On the other
hand, adult mice seem to be resistant to similar insults
(Veronesi et al., 1991) and present axonal degeneration and
paralysis only after long exposure up to 9 months to these com-
pounds (Lapadula et al., 1985).
This AOP has as a MIE the binding of OPIDN inducers to NTE,
which is followed by the cellular KEs: NTE inhibition and ‘‘aging’’,
disruption of Ca2+ homeostasis, mitochondrial dysfunction and dis-
ruption of neuronal cytoskeleton. These cellular effects result in
peripheral sensory and motor distal axonopathy that is manifested
as peripheral neuropathy (Fig. A3).
Here, for illustrative purposes, we explore two different types of
pairs of KEs from this AOP in an attempt to apply the evolved WoE
considerations based on Table 1. More speciﬁcally, the relationship
between inhibition and ‘‘aging’’ of NTE and increase of intracellular
Ca2+ (KER1), as well as increase of intracellular Ca2+ and mitochon-
drial dysfunction (KER2) are discussed.
Fig. A3. Depiction of the AOP for binding of certain organophosphates to neuropathy target esterase (NTE) leading to development of delayed peripheral neuropathy.
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A.3.1.1. Biological plausibility of KER1
The biological plausibility of the relationship between inhibition
and ‘‘aging’’ of NTE and increase of intracellular Ca2+ (KER1) is low
(weak). While there is considerable understanding of the molecular
interactions and pathways involved in OP delayed neurotoxicity, the
exact mechanism that would explain how inhibition and ‘‘aging’’ of
NTE indirectly leads to disruption of Ca2+ homeostasis is not known.
Several in vitro and ex vivo studies using brain tissue from treated
hens support that OPIDN inducers can ‘‘age’’ NTE, whereas other
OPs are capable of binding to the active site of NTE and inhibiting
its activity without causing ‘‘aging’’, and consequently, without pro-
ducing OPIDN (reviewed in Hargreaves, 2012). However, the events
that occur between NTE ‘‘aging’’ and the manifestation of clinical
symptoms that characterize OPIDN are not fully understood. It has
been suggested that NTE ‘‘aging’’ is followed by an increase in intra-
cellular Ca2+ that affects neuronal cytoskeleton leading to axonal
degeneration (reviewed in Emerick et al., 2012).
A.3.1.2. Essentiality of KER1
With respect to essentiality, only indirect evidence exists to
support this KER. This indirect evidence shows that when Ca2+
channel blockers are administered to animals prior to OP exposure
there is a reduction of OPIDN symptoms and most importantly, the
same blockers given after certain OP exposures signiﬁcantly pro-
tect and alleviate the clinical symptoms (Emerick et al., 2012). In
an experimental study, co-exposure of rats to a Ca2+ channel
blocker and dichlorvos prevented neurobehavioral alterations
induced by dichlorvos but no prevention of NTE inhibition has
been found (Choudhary and Gill, 2001). Although the essentiality
of this KE (increase of intracellular Ca2+) is strong for all the down-
stream KEs and AO, the same is not valid for the relationship
between NTE aging and the increased intracellular Ca2+ levels
(Bal-Price et al., 2015).A.3.1.3. Empirical support of KER1
Experiments have yet to be conducted to directly address
dose–response relationships between these two KEs. Therefore,
only indirect evidence can be used to evaluate WoE for this
KER. The extensive set of studies reviewed in Emerick et al.
(2012) to assess the reversibility and protection by Ca2+ chan-
nel blockers at the organ and organism levels used several
OPIDN inducers at concentrations that are known to cause
NTE inhibition and ‘‘aging’’. With respect to temporal concor-
dance, the NTE inhibition appears in a much earlier time point
than the increase in intracellular Ca2+ levels. For example, the
administration of dichlorvos to rats showed brain NTE inhibi-
tion up to 65.2% compared to controls after 24 h and recovery
of the enzyme up to 84% before the manifestation of clinical
signs (day 21), whereas the maximum increase (2.74-fold) in
free ionic Ca2+ in the cytosol was observed on day 15 and kept
high with slight drop until day 21 (Choudhary and Gill, 2001).
In terms of consistency across species, NTE is highly conserved
across species including mammals, insects, nematodes, and
yeast (Moser et al., 2000). The same is observed for the Ca2+
homeostatic system that is known to be highly conserved
throughout evolution (Case et al., 2007). Hens have been
mainly used in studies of OPIDN, however, rats have also been
demonstrated to be a valid model showing susceptibility and
NTE inhibition but no appearance of locomotor ataxia that is
evident in hens and humans after exposure to OPIDN inducers.
It is suggested that these differences in locomotor ataxia may
be due to differences in toxicokinetics and more rapid recovery
of NTE in the rat brain compared to other species. Regarding
the evaluation of consistency based on empirical data, there
is high degree of uncertainty of the relationship between inhi-
bition and ‘‘aging’’ of NTE and disruption of Ca2+ homeostasis,
which derives mainly from the lack of knowledge on the mech-
anism/s involved. Consequently, through an overall WoE evalu-
ation, the linkage between inhibition and ‘‘aging’’ of NTE and
disruption of Ca2+ homeostasis (KER1) is considered weak.
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A.3.2.1. Biological plausibility
There is substantial mechanistic understanding (Giorgi et al.,
2008) about the interrelationship between disruption of Ca2+
homeostasis and mitochondrial dysfunction; therefore biological
plausibility is considered to be strong. This interdependence of
the two KEs is highly important for cells with elevated energy
demands such as neuronal cells. Although there are several cellular
organelles that regulate Ca2+ homeostasis, mitochondria are of spe-
cial importance compared to the others as they can initially con-
tribute to the uptake of excessive Ca2+ and later to the release of
this ion under certain conditions (Giorgi et al., 2008).
A.3.2.2. Essentiality
The essentiality of the disruption of Ca2+ homeostasis for this
AOP is rated strong as it has been already discussed above. In con-
trast, no studies directly assessing the essentiality of mitochondrial
dysfunction in relation to the AO are available, whereas there is
limited experimental evidence supporting the essentiality of this
KE in relation to downstream cellular KE cytoskeletal dysfunction
(reviewed in Hargreaves, 2012), suggesting that this KE can be
rated as moderate.
A.3.2.3. Empirical support
Regarding temporality, the understanding of the relationship
between disruption of Ca2+ homeostasis and mitochondrial dys-
function (KER2) is considered to be moderate, because just as col-
lapse of Ca2+ homeostasis can lead to mitochondrial dysfunction,
mitochondrial dysfunction can also contribute to increased intra-
cellular Ca2+. Morphological changes in mitochondria have been
shown to appear early (day 5) following exposure of hens to
TOCP and moreover, these alterations further developed in a
time-dependent manner leading to neuronal loss (Mou et al.,
2006) however empirical data is lacking – no measurement of
Ca2+ has been performed. Thus, direct empirical support is lacking
at this time.
In conclusion, although the biological plausibility of the linkage
between Ca2+ homeostasis and mitochondrial dysfunction for this
AOP is strong, in the absence of empirical data and due to the lack
of established temporality between the two KEs, the overall WoE
for KER2 is considered to be moderate.
A.3.3. WoE conclusions
TheWoE of KER1 (the linkage between inhibition and ‘‘aging’’ of
NTE and disruption of Ca2+ homeostasis) is considered weak. The
WoE for KER2 (increase of intracellular Ca2+ leading to mitochon-
drial dysfunction) is considered to be moderate.A.4. Case example: agonist binding to estrogen receptor a
leading to an increased risk of endometrial cancer: evaluation
of a subset of KEs and KERs
Estrogens are important regulators of development and func-
tioning of the reproductive system in female, but also male higher
vertebrates. They also inﬂuence many physiological processes not
strictly related to reproduction, including cardiovascular health,
bone physiology, cognition, and behavior (reviewed by Deroo and
Korach, 2006; Heldring et al., 2007). Aberrant exposure to estro-
gens can lead to diseases in target organs. For instance use of estro-
gens, without addition of synthetic progesterone compounds, can
lead to an increased risk of endometrial cancer, on the order of
2–12-fold; use for 5–10 years appears to lead to the greatest risk(http://www.drugs.com/pro/estradiol.html#ID_690ebdc9-1c4f-
843a-e6a8-1e21f7aa7da9). The pathways of estrogen action in
stimulating endometrial growth have been well characterized,
with an early key event being transcription of target genes (see
for example, Gielen, 2005; citebib26; Heldring et al., 2007). Such
sustained exposure to estrogens, in the absence of the addition of
progesterone agents, can lead to endometrial hyperplasia, which
may be a precursor to endometrial cancer. Using an animal model,
Moggs et al., 2004 reports estrogen effects on the endometrium,
speciﬁcally noting that it ‘‘. . .begins with the induction of genes
involved in transcriptional regulation and signal transduction and
is followed, sequentially, by the regulation of genes involved in
protein biosynthesis, cell proliferation, and epithelial cell differen-
tiation. Furthermore, we have identiﬁed genes with common
molecular functions that may drive ﬂuid uptake, coordinated cell
division, and remodeling of luminal epithelial cells.’’
For illustrative purposes, we focus on one KER in the AOP; the
KER between estrogen receptor a (ERaÞ binding by an agonist
(MIE) and transcriptional activation (KE1) (Fig. A4). A wide number
of transcripts could potentially be evaluated, as indicated in Moggs
et al., 2004. In practice, transcriptional activation of ERa can be
accurately assessed via reporter genes containing estrogen respon-
sive elements as the sole responsive elements (Sonneveld et al.,
2006). Test guidelines have been formulated that can be updated
regularly, describing detailed procedures to carry out such reporter
gene assays (OECD, 2009, 2012; EDSP, 2009). Other possibilities to
measure transcriptional activation through estrogen receptor a
include measurement of ligand-induced expression of endogenous
target genes that are expressed in target cells. This can have prac-
tical advantages showing responses in intact organisms allowing
linkage of estrogen receptor activation to adversity, but also has
drawbacks with respect to speciﬁcity and interpretation of the
results. The main problem with respect to speciﬁcity is the possi-
bility of regulation by other transcription factors of these target
genes, of which some factors may be inﬂuenced by the chemical
which is under investigation as the potential ERa activating com-
pound. In addition, because of overlapping activities it can be dif-
ﬁcult to distinguish between ERa and ERb activating compounds
(Kuiper et al., 1998). Therefore, it may be preferable to couple test-
ing using less selective tests with methods that use a more selec-
tive test (i.e. a selective, validated reporter gene assay), or a
speciﬁcity control using a receptor antagonist.
A.4.1. Biological plausibility (KER between estrogen receptor a binding
by an agonist (MIE) and transcriptional activation (KE1))
The main endogenous physiological estrogen is 17b-estradiol,
while strong synthetic ligands such as diethylstilbestrol have been
designed for pharmaceutical applications. In addition, many
ligands are known from a variety of sources, often much weaker
than aforementioned ones, including phytoestrogens and chemi-
cals with unintended weak estrogenic action that have been linked
to endocrine disruption (McLachlan, 2001). Some ligands can act as
antagonists, diminishing or even blocking the action of agonistic
ligands (Deroo and Korach, 2006; Heldring et al., 2007). Most of
the effects of estrogens are mediated through the estrogen recep-
tors (ERs), ERa (NR3A1) and ERb (NR3A2), conserved proteins
evolving from a common vertebrate ancestor (Thornton, 2001).
These receptors belong to the nuclear hormone receptor family
and have distinct domains that have different functions, such as
ligand binding as well as those mediating DNA binding and tran-
scriptional activation upon ligand binding. Modulation of tran-
scriptional activity can occur through cross-talk with other
signaling pathways through phosphorylation, or protein–protein
interactions. In addition, some estrogen effects are mediated
through non-genomic actions as a result of signaling by estrogen
Fig. A4. Depiction of the AOP of agonist binding to estrogen receptor a leading to an increased risk of endometrial cancer.
532 R.A. Becker et al. / Regulatory Toxicology and Pharmacology 72 (2015) 514–537receptors bound through adapter proteins to membrane receptors
(Deroo and Korach, 2006; Heldring et al., 2007). There are few
uncertainties and there is little conﬂicting evidence with respect
to the relationship of agonist binding to ERa and transcriptional
activation. The KER relationship is highly conserved in mammals
and higher vertebrates, and there are many well documented
examples. The estrogen receptor is expressed in all vertebrates
and even classes of invertebrates. Evidence suggests, however, that
some invertebrate and low vertebrate ER do not bind 17b-estradiol,
showing that care should be taken in extrapolating this KER when
considering effects in lower species (Paris et al., 2008).
The biological plausibility of the KER between ERa binding
(MIE) and subsequent transcriptional activation (KE1) by agonistic
ligands is considered high (strong). An extensive body of scientiﬁc
evidence has accumulated documenting the pathway linking ERa
agonist binding and induction of transcription. In brief, there is a
direct link between binding of receptor agonists and transcrip-
tional activation. The transcriptional activation of target genes is
a result of binding of the receptor to speciﬁc binding sites (estrogen
responsive elements) in promoter regions of these genes, and tran-
scription occurs through a series of steps that include co-regulator
recruitment and through this increased transcription of target
genes by the basic transcriptional machinery. These steps have
been analyzed in detail and described extensively in the literature.
Ligand-independent methods of activation have also been
described, that involve phosphorylation of the receptor via path-
ways activated by polypeptide growth factors. However, these
seem not to be involved in the majority of physiological functions
and do not play a signiﬁcant role in the KER interaction when
assessing the effect of ligands under well-deﬁned experimental
conditions, with constant levels of (serum-derived) polypeptide
growth factors.
The above strong linkage of transcriptional activation upon
ligand binding, however, does not apply to antagonists. These are
a subset of receptor binding compounds, that do not (in the case
of full antagonists), or only partially (in the case of partial antago-
nists), activate the receptor since the conformational change upon
receptor binding is such that no or different transcriptional
co-regulators are recruited. Essentiality of the relationship can befurther distorted if there is different metabolic capacity in the test
systems assessing receptor binding and transcriptional activation.
This can lead to metabolites with either stronger receptor binding
and transcriptional activation (e.g. in the case of methoxychlor) or
weaker activities (e.g. in the case of bisphenol A). In the case of
equal or absence of metabolic capacity in test systems this consid-
eration does not apply. Again, this shows the importance of using
well-deﬁned experimental systems and conditions in assessing
ERa activation.
A.4.2. Essentiality (KER between estrogen receptor a binding by an
agonist (MIE) and transcriptional activation (KE1))
The support for essentiality of this KER is considered high
(strong). Essentiality is clearly demonstrated in studies that use
antagonists (e.g. Tremblay et al., 1998). In addition, estrogen
effects are clearly linked to expression of estrogen receptors and
mutations in the receptor that prevent ligand binding also prevent
transcriptional activation. Furthermore, ER knock-out animals
show strongly impaired reproductive functions (Deroo and
Korach, 2006; Heldring et al., 2007)
A.4.3. Empirical support (KER between estrogen receptor a binding by
an agonist (MIE) and transcriptional activation (KE1))
The empirical support of KERs is considered high (strong). There
is extensive detailed understanding of the KER, including the
sequence and the manner in which ligands bind to and alter the
conformation of ERas, the binding of the ligand–receptor complex
to DNA, recruitment of transcriptional co-regulators and subse-
quent transcriptional activation. Extensive dose–response relation-
ships with multiple chemicals are available showing concordance
between receptor binding and transcriptional activation
(Sonneveld et al., 2006). Transcriptional activation can be mea-
sured with a reporter gene assay. In these assays ERa activation
is measured with a reporter gene consisting of the estrogen
responsive elements coupled to a gene coding for a protein which
can be easily and speciﬁcally measured (e.g. luciferase or green ﬂu-
orescent protein) (Legler et al., 1999).
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The WoE of KER1 (agonist binding to ERa leading transcription)
is high (strong).A.5. A chemical speciﬁc case example: induction of cytotoxicity
and regenerative hyperplasia by oral hexavalent chromium
(Cr(VI)) leading to duodenal tumors in mice
In this AOP case example, we focus on the tumor promotional
mode of action produced by high oral doses of chromium VI
(CrVI) in mice. As an AOP case example applicable to a single
chemical or a very limited number of chemicals (OECD AOP
Project Proposal Guidance (OECD, 2009)), the WoE evaluation is
largely limited to the evidence developed for the chemical for
which the AOP has been constructed. As discussed in Section 4.6,
the role of chemical speciﬁc AOPs, as knowledge on this MOA
increases, the breadth of application of a chemical-speciﬁc case
example could expand to a broader chemical domain.
In the intestinal tract as well as other tissues, the multistep pro-
cess of carcinogenesis is characterized by the canonical phases of
initiation, promotion, and progression. The initiation phase is gen-
erally considered to result from mutations that may occur sponta-
neously or through exposure to chemicals. The tumor promotion
phase typically requires a sustained cellular growth/cell prolifera-
tion stimulus as well as inhibition of apoptosis of initiated cells.
These initiated cells thus acquire a selective advantage and
undergo clonal expansion to form small foci of altered cells and,
eventually, tumors. These foci of altered/initiated cells have been
extensively characterized in colonic crypts in rodents and humans
where they are clearly visible during histopathological examina-
tion (Cheng and Lai, 2003; Takahashi and Wakabayashi, 2004).
Duodenal tumors in mice are believed to originate from muta-
tions in the stem cells that reside at the base of the intestinal
crypts. A small number of stem cells located near the base of the
crypts of Lieberkühn give rise to proliferating progenitor or transit
amplifying (TA) cells (Chia and Kuo, 2010; Shaker and Rubin,
2010). The TA cells occupy the length of the crypts and give rise
to eight different types of intestinal cells, including the absorptive
enterocytes. Complete turnover of the epithelium occurs every 3–
5 days in an orderly fashion along the crypt–villus axis as entero-
cytes move upward to the villi. TA cells differentiate to become
and replace older enterocytes that are sloughed off into the intesti-
nal lumen.
Exposure to certain non-genotoxic agents at sufﬁciently high
doses can cause cytotoxicity to differentiated intestinal villous
cells. If the exposure is episodic, a burst of proliferation in the
crypts will occur to re-populate the cells lost due to cytotoxicity.
However, if the exposure is sustained and produces prolonged
cytotoxicity, a correspondingly sustained cell proliferation is
induced. In such a situation, such high rates of proliferation create
a situation in which insufﬁcient time exists to repair any DNA
damage occurring spontaneously or from genotoxic agents. Thus,
miss-repair of DNA that leads to mutations also becomes more
likely in this sustained proliferative environment.
Both inhibition of apoptosis and the proliferative environment
serve to promote the growth of spontaneously initiated cells.
Intestinal initiation/promotion models indicate the MOA of induc-
tion of adenocarcinomas involves cytotoxicity and regenerative
cell proliferation, a common mechanism in the MOA of many
tumors (Cohen and Arnold, 2011; Pitot et al., 2000). In the duode-
num of the mouse, tumorigenesis can occur ‘‘by a non-genotoxic
MOA involving cytotoxicity and regenerative cell hyperplasia’’
and such a MOA has been characterized as exhibiting ‘‘a clear dose
threshold’’ (USEPA, 2004). Studies with captan have shown that ifthe cytotoxic doses are discontinued, the tumor promotion
responses are reversible, leading EPA to accept that ‘‘there is a
strong causal association (dose–response, temporality) indicating
that tumor formation is secondary to cytotoxicity and hyperplasia
and that the latter is a KE in the sequential cascade of events lead-
ing to cancer’’ (USEPA, 2004). The fungicide folpet, similar in struc-
ture to captan, also appears to act via a similar mechanism (Cohen
et al., 2010; Gordon et al., 2012)
Duodenal tumors have more recently been observed in mice
following oral exposures to CrVI (National Toxicology, 2008).
Subsequently, an extensive research program was undertaken to
characterize the MOA and dose-dependent sequence of events
leading to intestinal tumor formation in mice. Based on these stud-
ies the hypothesized sequence of events leading to the AO of duo-
denal tumors in mice from oral exposures to CrVI in drinking water
is depicted as an AOP (Fig. A5).
A.5.1. Biological plausibility (non-genotoxic induction of cytotoxicity
and regenerative hyperplasia by a threshold mechanism promotes
duodenal tumors in mice)
The WoE for biological plausibility is high (strong). There is
textbook level understanding that turnover of normal villi occurs
by migration of epithelial cells from the base of the intestinal
crypts, and that stem cells within the crypts serve as the source
of these new epithelial cells (Johnson, 2013). Similarly, hyperplasia
in intestinal crypts is a well-documented response to villous cyto-
toxicity. Although the theoretical mechanism by which villous
cytotoxicity leads to crypt hyperplasia is well established (see
Thompson et al., 2013), direct evidence of a resulting proliferative
molecular signal, such as a change in cytokine concentration in
enterocytes is lacking. Prolonged cytotoxicity associated with
regenerative hyperplasia is a well-documented MOA for tumor
promotion in a number of tissues for a large range of chemicals
in numerous animal models (Boobis et al., 2009; Cohen and
Arnold, 2011). This tumor promotion MOA (prolonged exposure
at sufﬁciently high doses leading to sustained tissue injury) has
been described in toxicology textbooks since the mid-1980s (e.g.
Casarett and Doull’s Toxicology, third ed., 1986).
A.5.2. Essentiality
Chronic cytotoxicity in enterocytes in small intestine villi in
mice is the MIE. Oral doses that cause such chronic cytotoxicity
(e.g. CrVI doses that signiﬁcantly exceed the gastric reducing
capacity for an extensive period of time) cause crypt hyperplasia
and eventually tumorigenesis in the mouse intestine. At doses that
do not exceed the reducing capacity, cytotoxicity is not observed,
and normal cellular homeostasis appears to be maintained
(Thompson et al., 2011, 2012, 2013).
Thus, evaluation of essentiality is focused on the KER of cytotox-
icity leading to hyperplasia/proliferation. Destruction of villous
enterocytes (caused by doses that exceed cellular mechanisms
which maintain homeostasis) causes the production of a prolifera-
tive signal to the crypt stem cells and resulting hyperplasia in the
crypts. Very recent evidence indicates that following exposure of
mice to 180 mg/L CrVI in drinking water, chromium occurs close
to background levels within cells in the crypt whereas the chro-
mium levels in villous cells were reported to be more than thirty
fold higher (Thompson et al., 2015). This ﬁnding supports the idea
that crypt hyperplasia occurs in response to villous cytotoxicity.
The evidence for essentially is moderate. In the mouse, hyper-
plasia does not occur at doses below those that cause villous ente-
rocyte cytotoxicity. Evidence of essentiality is supported by the
NTP studies in rats; speciﬁcally, villous blunting indicative of cyto-
toxicity did not occur in rats treated with oral doses of CrVI) that
Fig. A5. Depiction of the AOP of induction of cytotoxicity and regenerative hyperplasia by oral CrVI leading to duodenal tumors in mice.
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neither crypt hyperplasia nor intestinal tumors were seen in the
NTP bioassay in rats. The evidence is determined to be less than
strong because direct evidence such as from reversibility studies
is not available at this time for CrVI. However, stop/reversibility
studies with captan have shown that the tumor promotion
responses are reversible, leading EPA to accept that ‘‘there is a
strong causal association (dose–response, temporality) indicating
that tumor formation is secondary to cytotoxicity and hyperplasia
and that the latter is a KE in the sequential cascade of events lead-
ing to cancer’’ (USEPA, 2004).A.5.3. Empirical support
The empirical support for each KE/KER is summarized below.
Overall, the empirical support for the AOP is judged to be moderate
to high (strong). As noted below, additional studies could provide
greater knowledge that may bolster the WoE for a number of
KEs/ KERs in this AOP.A.5.3.1. Empirical support of pre-MIE events
The pre-MIE events for this case example AOP include: (1)
reduction in the stomach and upper GI tract to CrIII; (2) absorption
of any CrVI that is not reduced in the GI tract through sulfate and
phosphate transporters by enterocytes (the columnar epithelial
cells that form the intestinal villi). Note – CrIII is much less
bioavailable than CrVI, thus extracellular reduction of CrVI to
CrIII in the stomach is protective against the toxic and carcinogenic
effects of oral exposure to CrVI (De Flora et al., 1997; De Flora,
2000; Proctor et al., 2012; Schlosser and Sasso, 2014). In terms of
empirical support, a dose-dependent increase of chromium in duo-
denal epithelium has been observed. Although CrVI cannot be spe-
ciated in tissues, a signiﬁcant increase in intestinal tissue
chromium concentration is observed for concentrations greater
than 5 mg/L CrVI (Thompson et al., 2013).A.5.3.2. Empirical support of KER1 (doses exceeding the gastric
reducing capacity lead to cytotoxicity in intestinal villi)
At sufﬁciently high oral doses of CrVI (e.g. doses that exceed the
gastric reducing capacity), cytotoxicity is induced in the villous cells
of the small intestine through contact with CrVI exiting the pylorus.
This is observed and evaluated histopathologically as cytoplasmic
vacuolization and blunting of the villi. A clear dose-threshold has
been observed for these cytotoxic effects (Thompson et al., 2011).
The empirical support of this KER is high (strong).
 Dose–response: villous cytotoxicity, measured by cytoplasmic
vacuolization and villous atrophy has been reported to occur
in a dose dependent fashion at doses which reduce/deplete
capacity to reduce CrVI (Thompson et al., 2013).
 Temporal concordance: At 8 days, cytotoxicity was observed at
170 and 520 mg/L Sodium dichromate dihydrate (SDD). At
91 days, cytotoxicity was observed at 60 mg/L or greater, and
at 2 years at 14.3 mg/L or greater.
 Incidence: neither NTP (2007) nor NTP (2008) report the inci-
dence of cytotoxicity. Thompson et al. (2011) reported that
cytoplasmic vacuolization in the duodenal villi was the most
sensitive end point occurring at 170 and 60 mg/L SDD at days
8 and 91, respectively; while atrophy of the villi and crypt
hyperplasia were ﬁrst evident at higher concentrations (i.e.
520 and 170 mg/L on days 8 and 91, respectively).
A.5.3.3. Empirical support of KER2 (sustained cytotoxicity triggers
crypt cell proliferation)
Hyperplasia occurs when stem cells in the crypts experience a
prolonged stimulus to generate new epithelial cells. This is
observed and evaluated histopathologically (Thompson et al.,
2011, 2012, 2013). The empirical support of this relationship is
high (strong).
 Species speciﬁcity: diffuse hyperplasia occurred in the duode-
num of mice at all SDD concentrations examined in the 2-year
bioassay, while there was no evidence of diffuse hyperplasia
in the rat duodenum at any dose level.
Table A.5.3.5
Dose-response, temporal and incidence concordance of histopathological lesions in
mice treated orally with CRVI.a
Females (dose) mg/kg-day 0 14 57 172 519
Diffuse hyperplasia 0% 32% 70% 62% 84%
Adenoma 0% 0% 4% 26% 24%
Carcinoma 0% 0% 0% 2% 12%
Males (dose) mg/kg-day 0 14 57 172 519
Diffuse hyperplasia 22% 36% 84% 84% 64%
Adenoma 2% 0% 2% 10% 30%
Carcinoma 0% 0% 0% 4% 6%
a From NTP (2008) and Thompson et al. (2011).
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relationships between cytoplasmic vacuolization in villi (a mar-
ker of cytotoxicity) and crypt hyperplasia have been published
by Thompson et al. (2013):
 At Day 8: at 500 mg/L 100% cytoplasmic vacuolization and
60% crypt hyperplasia; at 170 mg/L 60% cytoplasmic vac-
uolization and 0% crypt hyperplasia; at 60 mg/L 0% cytoplas-
mic vacuolization and 0% crypt hyperplasia.
 At Day 91: at 500 mg/L 70% cytoplasmic vacuolization and
90% crypt hyperplasia; at 170 mg/L 100% cytoplasmic vac-
uolization and 90% crypt hyperplasia; at 60 mg/L 50% cyto-
plasmic vacuolization and 0% crypt hyperplasia.
A.5.3.4. Empirical support of KER3 (crypt hyperplasia leads to an
increased probability of spontaneous mutations in cells within the
crypt)
The KE is postulated as sustained increase in proliferation, a
more rapid cell cycle leading to increases in the probability of
miss-repair of DNA and the ﬁxation of spontaneous mutations in
daughter cells. The exact relationship between the crypt hyper-
plasia and the occurrence of crypt cell mutations is not exactly
known. The increase in stem cell population and number of cells
transiting and dividing as they move up the villus likely leads to
increased spontaneous mutation. Potential contributors to the pro-
liferative environment may be the oxidative damage caused by
CrVI entering the enterocytes resulting in anti-oxidant responses
and inﬁltration of immune cells (NTP, 2008; Thompson et al.,
2011, 2012, 2013). The empirical support of this relationship is
moderate.
 Methodologies to measure spontaneous mutations are lacking,
so the empirical evidence of this relationship is indirect.
 The evidence for a direct mutagenic mode of action of CrVI on
duodenal epithelial cells is negative. O’Brien et al. (2013)
reported no treatment-related effect Kras codon 12 even at
the high CrVI doses that were carcinogenic in the 2-year bioas-
say and that increased crypt proliferation after 7 or 90 days of
exposure. Furthermore, toxicogenomic data from mice exposed
to CrVI for 90 days did not indicate changes in Apc gene
expression.
A.5.3.5. Empirical support of KER4 (sustained increase in spontaneous
mutations and sustained proliferative stimulus leads to formation of
benign and malignant tumors)
An increase in spontaneous mutations coupled with sustained
proliferative stimulus over a signiﬁcant portion of the lifespan of
the mouse provides a selective growth advantage to spontaneous
initiated intestinal cells. The KE is formation of benign and malig-
nant tumors due to clonal expansion and selection of cells that
have lost normal growth regulatory controls. The empirical sup-
port of this relationship is high (strong). Again, the evidence isindirect, because empirical evidence of generation of spontaneous
mutations is lacking.
 Dose-response: the dose-response, temporal and incidence
relationships between hyperplasia in the duodenum in mice
and adenomas and carcinomas of the duodenum are summa-
rized in Table A.5.3.5.
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